AUAUniversity: Recent Episodes
AUAUniversity
The AUAUniversity podcast is an official podcast of the American Urological Association. More information can be found at https://auau.auanet.org
Update Series (2026): Case Based Medical and Surgical Management of Peyronie's DiseaseHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Matthew Ziegelmann, MDNow in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org
AUA2026: Contemporary Management of Advanced Prostate Cancer: Guidelines and BeyondCME Available: https://cme.auanet.org/URL/26DC040ONLLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to: 1. Identify appropriate use of genetic testing, genetic counseling as well as somatic testing.2. Describe appropriate use of treatment-related to specific genetic alterations.3. Identify appropriate combination therapy with ADT plus novel androgen receptor pathway inhibitors and chemotherapy. Early treatment intensification as well as appropriate de intensification will be discussed in mHSCPC.4. Describe the treatments for non-metastatic CRPC and oncologic outcomes based on AUA/SUO and NCCN Guidelines.5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO and NCCN Guidelines.ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstellasLantheus Medical ImagingNovartis Pharmaceuticals CorporationPfizer, Inc
AUA2026: Focus on: Muscle Invasive Bladder CancerCME Available: https://cme.auanet.org/URL/FOCUS266ONLLEARNING OBJECTIVES:After participating in this CME activity, participants will be able to:1. Evaluate limitations in the current MIBC treatment landscape including patient outcomes and gaps in available systemic therapies to identify individuals with limited or no effective treatment options and enhance clinical decision-making.2. Interpret the mechanisms of action and clinical data supporting antibody-drug conjugates (ADCs) to determine their potential role in addressing unmet therapeutic needs in patients with MIBC who are ineligible for traditional treatment pathways.3. Incorporate evidence-based perioperative systemic treatment strategies including neoadjuvant and adjuvant approaches into patient care algorithms to improve pathologic response rates and survival outcomes in MIBC.4. Apply best practices for managing and mitigating adverse events associated with emerging systemic and perioperative therapies to optimize treatment adherence and patient safety in the MIBC setting.5. Implement strategies for effective communication, multidisciplinary care coordination, and shared decision-making between urologists, medical oncologists, and patients to improve treatment alignment and patient-centered outcomes in MIBC.ACKNOWLEDGEMENTS:Support provided by an independent educational grant from:Pfizer, Inc.
AUA2026: Focus on: ADT in the Modern Era - Balancing Cancer Control and Cardiovascular SafetyCME Available: https://cme.auanet.org/URL/FOCUS265ONLLEARNING OBJECTIVES:After participating in this CME activity, participants will be able to:1. Integrate cardiovascular (CV) risk assessment into ADT initiation by applying key findings from the REVELUTION-1 trial to identify patients at elevated risk for atherosclerosis and MACE.2. Compare and apply the CV safety profiles of LHRH agonists versus GnRH receptor antagonists to guide personalized ADT selection in patients with varying CV risk.3. Implement streamlined monitoring strategies for men on oral ADT, including testosterone levels, lipid and blood pressure evaluation, and surveillance for early CV risk indicators.4. Collaborate with cardiology and primary care to optimize statin use and coordinate CV risk-reduction strategies for prostate cancer patients receiving ADT.5. Strengthen shared decision making and adherence by incorporating discussions of oncologic benefit, CV risk, and mitigation strategies into routine oral ADT counseling and follow-up.ACKNOWLEDGEMENTS:Support provided by independent educational grants from:Pfizer, IncSumitomo Pharma America, Inc.
Innovations in the Surgical Management of BPH (2026)CME Available: https://cme.auanet.org/URL/surgical-treatment-bph-2026LEARNING OBJECTIVES: After participating in this educational series, participants will be able to:1. Utilize the newly released AUA Guidelines Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice.2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.ACKNOWLEDGEMENTS:Support provided by independent educational grants from:- Olympus Corporation of the Americas- Teleflex Interventional Urology© 2026 AMERICAN UROLOGICAL ASSOCIATION. ALL RIGHTS RESERVED.ATTENTION: You are prohibited from using or uploading content you accessed through this activity into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Update Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based ApproachNow in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026
AUA Guidelines: Advanced Prostate CancerHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Kristen R. Scarpato, MD, MPHTo access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer
AUA Guidelines: Clinically Localized Prostate CancerHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: James Eastham, MD, FACSTo access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer
Update Series (2026): Kidney Stones and the Infected PatientHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Mantu Gupta, MDNow in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org
AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer WebcastCME Available: https://cme.auanet.org/URL/FOCUS262ONLLEARNING OBJECTIVES:After participating in this CME activity, participants will be able to:1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care.2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging.3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them.4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments.5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy).ACKNOWLEDGEMENTS:Support provided by independent educational grants from:Blue Earth Diagnostics, Inc.Lantheus Medical Imaging
Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice GuidelinesNow in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026
AUA Guidelines: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic HyperplasiaHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Jaspreet S. Sandhu, MDTo access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/bph-guideline.Please note that access to the full guideline requires user login. If you do not already have an account, you can create a free login.
AUA2026: Society of Women in Urology MeetingHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Amy N. Luckenbaugh, MD, FACSTo register for AUA2026, please visit auanet.org/AUA2026/register!
Dr. Mark A. Preston, MD, MPHTo register for AUA2026, please visit auanet.org/AUA2026/register!
AUA2026: Society of Benign Prostate Disease MeetingHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Kevin Thomas McVary, MD, FACSTo register for AUA2026, please visit auanet.org/AUA2026/register!
AUA Guidelines: Early Detection of Prostate CancerHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Simpa Salami, MD, MPHLin DW, Carlsson S, Filson CP, et al. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).J Urol. 0(0).10.1097/JU.0000000000004995. https://www.auajournals.org/doi/10.1097/JU.0000000000004995
AUA2026: Sexual Medicine Society of North America MeetingHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Landon Trost, MD, To register for AUA2026, please visit auanet.org/AUA2026/register!
Urogenital Reconstruction (SUFU) MeetingHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Anne Pelletier Cameron, MD, URPS To register for AUA2026, please visit auanet.org/AUA2026/register!
Update Series (2026): At-Home Diagnostic and Therapeutic Options in Men's HealthHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Richard J. Fantus, MDNow in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org
AUA2026: Research Programming Preview: Amplifying the Impact of Research for Career DevelopmentHost: H. Henry Lai, MDGuest: Naveen Kachroo, MD, PhDJoining us today for this special episode brought to you by the AUA Office of Research, Research Education Committee, are Drs. H. Henry Lai and Naveen Kachroo discussing the dynamic research education programming planned at AUA2026. Head to auanet.org/AUA2026/register to check out the new and exciting programming at AUA2026 and to register!
Update Series (2026): Perioperative Management of Urinary Diversion: What Every Urologist Should KnowHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Rohit Reddy, MDNow in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org
AUA2026: Advanced Cystoscopy Training for APPsHost: Mark L. Gonzalgo, MD, PhD, MBAGuests: Brett Johnson, MD and Davis Viprakasit, MD, FACSTune in to hear straight from the experts about our newest Hands-On Skills Training offering - Advanced Cystoscopy Training for APPs, part of the pre-meeting programming at AUA2026! In this episode, Dr. Brett Johnson and Dr. Davis Viprakasit discuss all about what you can expect from the Advanced Cystoscopy Training for APPs, a new APP hands-on skills training being held at AUA2026. This training provides both a half-day of hands-on skills training in the most critical procedural areas of need for APPs, as well as a library of on-demand virtual didactics straight from the experts. Spaces are still available - for more information or to register, please visit https://www.auanet.org/AUA2026/program/pre-meeting-programsOutline:Segment #1: Why offer the Advanced Cystoscopy Training for APPs?Segment #2: Description of the courseSegment #3: Unique aspects of the courseSegment #4: Potential benefits to participantsSegment #5: Future directions
JohnsonLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning.2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC.3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.
JohnsonLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
JohnsonLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors.2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning.3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.
Management of ComplicationsNow in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit https://cme.auanet.org/URL/US2026
Co., Inc.LEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Define adjuvant therapy, review current clinical guidelines, and recognize the current landscape of treatment options for patients with RCC.2. Compare and contrast different adjuvant therapies available for RCC, including targeted therapies and immunotherapies.3. Identify common side effects associated with adjuvant therapies for RCC and provide strategies for managing and mitigating these adverse events in clinical practice.4. Discuss ongoing clinical trials and new therapeutic targets under investigation for adjuvant treatment of RCC.
Use of Suction Ureteroscopes for Kidney Stone Treatment: CVAC SystemHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Karen L. Stern, MD
Update Series: The Role of Nephrectomy in Advanced Kidney CancerHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Sarah P. Psutka, M.D., M.S., F.A.C.S.Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org
AI for Prostate Cancer Treatment Planning Host: Mark L. Gonzalgo, MD, PhD, MBAGuest: Wayne G. Brisbane, MD
AUA Guidelines: Salvage Therapy for Prostate CancerHost: Mark L. Gonzalgo, MD, PhD, MBAGuest: Yaw Nyame, MD, MS, MBAMorgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211(4):509-517. https://www.auajournals.org/doi/10.1097/JU.0000000000003892Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy. J Urol. 2024;211(4):518-525. https://www.auajournals.org/doi/10.1097/JU.0000000000003891Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. J Urol. 2024;211(4):526-532. https://www.auajournals.org/doi/10.1097/JU.0000000000003890
Dane Johnson, MDLai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part I Evaluation and Management Approach. J Urol. 0(0). doi:10.1097/JU.0000000000004564. https://www.auajournals.org/doi/10.1097/JU.0000000000004564Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J Urol. 0(0). doi:10.1097/JU.0000000000004565. https://www.auajournals.org/doi/10.1097/JU.0000000000004565Lai HH, Pontari MA, Argoff CE, at al. Male Chronic Pelvic Pain: AUA Guideline: Part III Treatment of Chronic Scrotal Content Pain. J Urol. 0(0). doi:10.1097/JU.0000000000004566. https://www.auajournals.org/doi/10.1097/JU.0000000000004566
JohnsonLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
JohnsonLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors.2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning.3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.
Una J. Lee, MDGenitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025)Kaufman MR, Ackerman LA, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 0(0). doi:10.1097/JU.0000000000004589. https://www.auajournals.org/doi/10.1097/JU.0000000000004589
JohnsonLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning.2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC.3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.
Core Curriculum: Surgical Management of UrolithiasisAUA Urology Core Curriculum: auau.auanet.org/coreHost: Mark L. Gonzalgo, MD, PhD, MBAGuests: Marcelino E. Rivera, MD and T. Max Shelton, MDOutline:Segment 1: Acute Stone Event and Radiographic EvaluationSegment 2: Shock Wave LithotripsySegment 3: UreteroscopySegment 4: Percutaneous NephrolithotomySegment 5: Intracorporeal LithotripsySegment 6: Special Considerations
Melissa R. Kaufman, MD, PhDRecurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025)Ackerman AL, Bradley M, D’Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004723
Update Series (2025) Lesson 30: Beyond Ureteropelvic Junction: Case-Based Tips and Tricks in Robotic Ureteral Stricture Reconstructive SurgeryNow in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25
The Latest Breakthroughs in LG-IR-NMIBC (2025) CME Available: auau.auanet.org/node/43689After participating in this CME activity, participants will be able to:1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes.2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns.3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments.4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval).5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies.6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery.ACKNOWLEDGEMENTSSupport provided by an independent educational grant from:UroGen Pharma, Inc.
The Latest Breakthroughs in mHSPCCME Available: https://auau.auanet.org/node/43825After participating in this CME activity, participants will be able to:1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC.2.Implement current clinical guidelines for biomarker testing in mHSPC.3.Explain the role of the PI3K/AKT pathway in prostate cancer biology.4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC.5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC.Acknowledgements: AstraZenecaBayer HealthCare Pharmaceuticals Inc.
AUA2025: Key Takeaways: Sexual Dysfunction HighlightsPresenter: Brittany Berk, MD & Arthur Burnett, MD, MBA
AUA2025: Key Takeaways: Female Urology HighlightsPresenter: Mitch G. Goldenberg, MD & Kathleen Kobashi, MD, MBA, FACS
AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic OpportunitiesPresenter: Rosalyn M. Adam, PhD
AUA2025: Ramon Guiteras Lecture: The Future of Healthcare: How Will Urology be Impacted?Presenter: Vin Gupta, MD, MPA
Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished)CME Available: auau.auanet.org/node/42040After participating in this CME activity, participants will be able to:1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.AcknowledgementsSupport provided by an independent educational grant from:Astellas and Pfizer, Inc.
AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)CME Available: https://auau.auanet.org/node/43009At the conclusion of this activity, participants will be able to:1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer.4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Update Series (2025) Lesson 18: Multidisciplinary Evaluation and Management of Pelvic Pain in WomenNow in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25
AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your PracticeCME Available: https://auau.auanet.org/node/43029At the conclusion of this activity, participants will be able to:1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer4. Discern the different prognostic endpoints provided by various genomic tests5. Recognize candidates for, and implications of, germline testing for prostate cancer.ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUA2025: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems CME Available: https://auau.auanet.org/node/43047At the conclusion of this activity, participants will be able to:1. Implement current practice guidelines and explain methods and resources to improve transurethral resection of a bladder tumor (TURBT) skills.2. Identify the best intravesical agent and duration of therapy for low-, intermediate-, and high-risk NMIBC and what to do during a BCG shortage.3. Identify methods to treat significant toxicities from various intravesical therapies.4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs.ACKNOWLEDGEMENTS:This educational activity is supported by an independent educational grants from:Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
The Surgical Management of BPH (2025)CME Available: https://auau.auanet.org/node/43193Acknowledgements: This educational series is supported by an independent educational grant from Olympus Corporation of the Americas.After participating in this CME activity, participants will be able to:1. Utilize the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia in practice.2. Determine the appropriate role and clinical expectation for current technologies, including pivotal studies, based on evidence.3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.
AUA2025: AUA Advanced Prostate Cancer CourseCME Available: https://auau.auanet.org/node/43035At the conclusion of this activity, participants will be able to:1. Describe appropriate use of genetic testing (germline) and understand the importance of genetic counseling.2. Describe appropriate use of somatic testing and treatments related to specific genetic alterations.3. Identify appropriate combination therapy with ADT plus novel androgen access therapies and chemotherapy. Early treatment intensification including patient selection and adverse effects and benefits will be discussed in mHSCPC.4. Explain the treatments for non-metastatic CRPC and oncologic outcomes, with recommendations based on AUA/SUO Guidelines.5. Counsel patients on available treatment options for CRPC as well as combination therapy and sequencing based on the latest AUA/SUO Guidelines.ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUA2025: Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future OpportunitiesCME Available: https://auau.auanet.org/node/43003At the conclusion of this activity, participants will be able to:1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.2. Identify the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.5. Identify the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUA2025: AUA Guidelines on Early Detection of Prostate Cancer: Maximizing Benefits, Minimizing HarmCME Available: https://auau.auanet.org/node/43021At the conclusion of this activity, participants will be able to:1. Apply the Early Detection of Prostate Cancer: AUA/SUO Guideline (2023), and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement.2. Maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically significant prostate cancer, while avoiding unnecessary biopsies and detection of clinically insignificant prostate cancers.3. Describe the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences.4. Identify available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use, and the clinical scenarios in which they are most valuable to be used.5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer and implement safe biopsy practices with respect to approach, avoidance of infection, and attention to patient comfort; understand the rationale for transperineal prostate biopsy and its technique; be able to establish a transperineal biopsy practice.ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUA2025: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical PracticeCME Available: https://auau.auanet.org/node/43015At the conclusion of this activity, participants will be able to:1. Describe key components of genetic risk assessment, genetic counseling, and informed consent for genetic testing.2. Describe elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers, and clinical actionability.3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic results in prostate cancer screening and management of both localized and advanced prostate cancer.4. Describe genetic causes, clinical manifestations, indication for genetic testing, and cancer risk associated with hereditary kidney cancer syndromes. Understand how genetic mutation can guide targeted therapy in patients with von Hippel-Lindau syndrome.5. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Highlights from AUA2025: Advances in NMIBC (2025)CME Available: https://auau.auanet.org/node/43167 At the conclusion of this CME activity, participants will be able to: 1. Recognize recent developments in the management of NMIBC. 2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events. 3. Employ current management approaches for NMIBC. 4. Utilize risk stratification to guide treatment decisions for NMIBC patients. 5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities. This educational activity is supported by independent educational grants from: Merck & Co., Inc. ImmunityBio, Inc.
AUA Guidelines: MicrohematuriaCo-Hosts: Daniel A. Barocas, MD, MPH & Stephen Boorjian, MDMicrohematuria: AUA/SUFU Guideline (2025)Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490. https://www.auajournals.org/doi/abs/10.1097/JU.0000000000004490
AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025 CME Available: https://auau.auanet.org/node/42997At the conclusion of this activity, participants will be able to:1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team.2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state.3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer.4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients.5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.
AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat ThemCME Available: https://auau.auanet.org/node/43041At the conclusion of this activity, participants will be able to:1. Confidently apply updated guidelines to the care of patients with non-muscle-invasive bladder cancer.2. Risk-stratify patients with non muscle- invasive bladder cancer.3. Adapt treatment choices depending on risk of disease, including consideration to the availability of bacillus Calmette-Guérin.4. Counsel and manage patients with bacillus Calmette-Guérin-unresponsive non muscle-invasive bladder cancer, including treatment selection with newly approved agents for BCG-unresponsive disease.5. Individualize patient surveillance according to risk stratification.6. Evaluate available urinary bladder cancer biomarkers and where to potentially utilize them in practice to inform management.ACKNOWLEDGEMENTSThis educational activity is supported by an independent educational grants from:Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate CancerCME Available: https://auau.auanet.org/node/43069At the conclusion of this CME activity, participants will be able to:1. Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring.2. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.3. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.4. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.5. Identify patients with radiorecurrent organ-confined prostate cancer.ACKNOWLEDGEMENTSSupport provided by independent educational grants from:Blue Earth Diagnostics, Inc.Lantheus Medical ImagingNovartis Pharmaceuticals Corporation
AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care TeamCME Available: https://auau.auanet.org/node/42822At the conclusion of this CME activity, participants will be able to:1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer.2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy.3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes.4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing.5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination.ACKOWLEDGEMENTSSupport provided by independent educational grants from:AstraZenecaMerck & Co., Inc.
Live from AUA2025: Advances in ADT ProgramCME Available: https://auau.auanet.org/content/LiveFromAUA2025#group-tabs-node-course-default1ACKNOWLEDGEMENTS:This educational activity is supported by independent educational grants from:Pfizer, Inc. Sumitomo Pharma America, Inc. At the conclusion of this CME activity, participants will be able to:1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings.3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT.4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes.5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT.6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.
AUA2025: Sexual Medicine Society of North America MeetingCohost: Landon Trost, MDOutline: Segment #1: What is the Sexual Medicine Society of North America and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting?Segment #3: What are the main clinical areas being highlighted at the SMSNA meeting at AUA2025?Segment #4: What is new or exciting on the horizon in your sub-specialty?Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SMSNA meeting at AUA2025?
AUA2025: Society of Urological Robotic Surgeons MeetingCohost: Michael D. Stifelman, MDOutline:Segment #1: What is the Society of Urological Robotic Surgeons and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting?Segment #3: What are the main clinical areas being highlighted at the SURS meeting at AUA2025?Segment #4: What is new or exciting on the horizon in your sub-specialty?Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the SURS meeting at AUA2025?
AUA2025: Focal Therapy Society MeetingCohost: Rafael Sanchez-Salas, MDOutline: Segment #1: What is the Focal Therapy Society and what unique value does it bring to its members and the broader field of urology. Segment #2: For the AUA2025 meeting, what can you tell us about the agenda and what the audience can expect from the meeting?Segment #3: What are the main clinical areas being highlighted at the FTS meeting at AUA2025?Segment #4: What is new or exciting on the horizon in your sub-specialty?Segment #5: What final message what you like to leave with listeners related to your sub-specialty and/or the FTS meeting at AUA2025?
Update Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care SettingUpdate Series 2025 Lesson 9: Congenitalism: Transitioning Patients with Congenital Urological Anomalies from the Pediatric to the Adult Care SettingNow in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25
AUA2025: Masterclass: Renal Access and Interventions (2025)Cohost: Rob Sweet, MD, FACS, MAMSE and Thomas Chi, MD, MBATune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Drs. Thomas Chi and Robert Sweet discuss Masterclass: Renal Access and Interventions, an all new interactive training offering skills in percutaneous renal access and image-guided renal interventions. Early Bird deadline for Hands-on Skills trainings has been EXTENDED - ends March 24. Spaces are limited – Register now!
Hereditary Kidney Cancer SyndromesCME Available: https://auau.auanet.org/node/41772ACKNOWLEDGEMENTS:Support provided by an independent educational grant from: Merck & Co., Inc. LEARNING OBJECTIVES:At the conclusion of this activity, participants should be able to:1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation.2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members.3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors.4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies.5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.
AUA2025: Fundamentals of Prostate MRI and Transperineal Interventions (2025)Cohost: Arvin K. George, MD and James Wysock, MD, MScTune in to hear straight from the experts about what you can expect from our NEWLY DESIGNED Full Day Hands-on Skills Trainings at AUA2025! In this episode, Dr. Arvin K. George and Dr. James Wysock discuss optimizing diagnosis of clinically significant prostate cancer along with a preview of what practicing urologists will gain from attending Fundamentals of Prostate MRI and Transperinal Interventions. Among the skillsets of MRI interpretation, segmentation, fusion-guided transperineal prostate biopsy, and transperineal spacer techniques, attendees also receive access to a library of on-demand virtual didactics straight from the experts!Early Bird deadline for Hands-on Skills trainings ends March 7. Spaces are limited – Register now! https://www.auanet.org/AUA2025/register/hands-on-skills-trainings Outline: Segment #1: The Changing Landscape of Prostate Cancer DiagnosticsSegment #2: Why Transperineal Biopsy?Segment #3: What Participants Will Learn - MRISegment #4: What Participants Will Learn – Transperineal TechniquesSegment #5: Why you should attend this course
Recognition and Management of Complications Following Gender Affirming SurgeryCo-Host: Laura Douglass, MD Outline: Segment #1 Topic: Why is this important for ALL urologists to know?Segment #2 Topic: Introduction to Gender Affirming Surgery (GAS)Segment #3 Topic: Emergency/ED consultations vs. Outpatient/clinic consultationsResources: - Hanley K, Wittenberg H, Gurjala D, Safir MH, Chen EH. Caring for Transgender Patients: Complications of Gender-Affirming Genital Surgeries. Ann Emerg Med. 2021 Sep;78(3):409-415.- Krakowsky Y, Shah G, Nguyen AV, Kavanagh AG, Potter E, Remondini T, Goldsher YW, Millman A. Gender-affirming care in urology: emergency care of the gender-affirming surgical patient-what the primary urologist needs to know. BJU Int. 2024 Feb;133(2):124-131. doi: 10.1111/bju.16249. Epub 2023 Dec 14. PMID: 38060336.- Mann RA, Kasabwala K, Kim N, Pariser JJ. The Management of Complications of Feminizing Gender Affirming Genital Surgery. Urology. 2021 Jun;152:67-73. doi: 10.1016/j.urology.2021.01.031. Epub 2021 Jan 23. PMID: 33493512.- Maffucci F, Clark J, Jun M, Douglass L. A Urologist's Guide to Caring for Transgender and Gender Diverse Patients. Urol Clin North Am. 2023 Nov;50(4):577-585. doi: 10.1016/j.ucl.2023.06.020. Epub 2023 Aug 9. PMID: 37775216.- Nikolavsky D, Hughes M, Zhao LC. Urologic Complications After Phalloplasty or Metoidioplasty. Clin Plast Surg. 2018 Jul;45(3):425-435. doi: 10.1016/j.cps.2018.03.013. PMID: 29908632.
AUA Guidelines: Diagnosis and Treatment of Infertility in MenCo-Host: Robert E. Brannigan, MDOutline:Segment #1 Topic: New Table 1 Reviewing “Common Terms” in Semen Analysis and Update to the WHO Semen Analysis Reference RangesSegment #2 Update to the WHO Semen Analysis Reference RangesSegment #3 Topic: Y Chromosome Microdeletion Testing Change in Testing GuidanceSegment #4 Topic: Pelvic MRI imaging is an option for men with suspected ejaculatory duct obstructionSegment #5 Topic: For couples with recurrent pregnancy loss, clinicians should evaluate the male partner with karyotype (Expert Opinion) and sperm DNA fragmentationDiagnosis and Treatment of Infertility in Men: AUA/ASRM GuidelineBrannigan RE, Hermanson L, Kaczmarek J, Kim SK, Kirkby E, Tanrikut C. Updates to male infertility: AUA/ASRM guideline (2024). J Urol. Published online August 15, 2024. doi:10.1097/JU.0000000000004180. https://www.auajournals.org/doi/10.1097/JU.0000000000004180
AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive BladderCo-Host: Anne Pelletier Cameron, MD, FRCSC, URPSSegment #1: Is this an update to the prior Guideline?Segment #2: What is new in the Diagnosis, ntitial Assessment and Initial Management of OAB?Segment#3: What does the Guideline say about Oral Medication?Segment #4: What's new in minimally invasive prodceduresSegment #5: UDS and CystoscopySegment #6: What is new and exciting on the horizion for OABSegment #7: Where to start and the most impactpact research in this areaThe AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive BladderCameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. https://www.auajournals.org/doi/10.1097/JU.0000000000003985
AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder CancerGuest: Jeffrey M Holzbeierlein, MDOutline:Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant cisplatin based chemotherapy or adjuvant immunotherapy. Segment #2: Guideline Statement 11-When performing a cystectomy in males the bladder, prostate cand seminal vesicles should be removed (no change) but in females clinicians should consider removal of adjacent reproductive organs based on individual disease characteristics and need to obtain negative margins. Organ sparing procedures in females should be considered based on disease location and characteristics on an individual basis. Segment #3: Guideline Statement 20-When performing bilateral pelvic lymphadenectomy , clinicians should remove, at a minimum, the external and internal iliac and obturator lymph nodes (standard lymphadenectomy).Segment #4: Future DirectionsTreatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO GuidelineHolzbeierlein J, Bixler BR, Buckley DI, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/SUO guideline (2017; amended 2020, 2024). J Urol. Published online April 25, 2024. doi:10.1097/JU.0000000000003981 https://www.auajournals.org/doi/10.1097/JU.0000000000003981
Biomarkers and Molecular Imaging for Prostate CancerCME Available: auau.auanet.org/node/41727ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.
Appropriate Use of Genetic Testing (who, what, when and how?)CME Available: auau.auanet.org/node/41734ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.
Treatment Intensification in Metastatic HSPCCME Available: https://auau.auanet.org/node/41733ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
Sequencing Of AgentsCME Available: auau.auanet.org/node/41735ACKNOWLEDGEMENTS:Support provided by independent educational grants from:Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.
Non-Muscle Invasive Bladder Cancer: Expert Guidance for UrologistsCME Available: https://auau.auanet.org/node/41961After participating in this CME activity, participants will be able to:1. Assess the risk stratification of low, intermediate, and high risk NMIBC patients to appropriately guide treatment decisions.2. Employ diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.3. Tailor treatment strategies based on individual patient characteristics and tumor biology to highlight the potential of personalized medicine in improving the management of NMIBC.4. Identify new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies.5. Properly manage adverse events associated with NMIBC treatment.AcknowledgementsSupport provided by an independent educational grant from:ImmunityBio, Inc.Merck & Co., Inc.UroGen Pharma, Inc.
Contemporary Management of MIBC and Beyond: Expert Guidance for UrologistsCME Available: https://auau.auanet.org/node/42040After participating in this CME activity, participants will be able to:1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.AcknowledgementsSupport provided by an independent educational grant from:Astellas and Pfizer, Inc.
Complex Cases in Kidney Stone DiseaseCME Available: https://auau.auanet.org/node/41889At the conclusion of this activity, participants will be able to:1. Describe the pathophysiology, genetic basis, and clinical presentation of Primary Hyperoxaluria Type 1.2. Analyze the unique considerations and challenges in evaluating kidney stones in pediatric patients.3. Utilize the results of 24-hour urine testing to guide dietary and pharmacologic interventions for stone prevention.4. Recognize the indications for genetic testing in patients with kidney stones and utilize the results to inform diagnosis and treatment.5. Employ appropriate patient management and family counseling strategies in consideration of the impact of genetic testing results.6. Properly refer patients with kidney stone disease to a nephrologist when warranted.ACKNOWLEDGEMENTS:Support provided by an independent educational grant from: Alnylam Pharmaceuticals, Inc.
Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24
AUA2024: Journal of Urology Lecture: Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of ColorPresenter: Quoc-Dien Trinh, MD, MBA
AUA2024: Ramon Guiteras Lecture: Modern Innovation: Promise or Peril?Presenter: Craig Niederberger, MD, FACS
AUA Leadership and Business Podcast: Urology Practice Manage - Overcoming Operational ChallengesThis episode is brought to you by the AUA Leadership and Business Podcast, where urologic professionals experience the practical application of business acumen essential to successfully navigating today’s rapidly changing business environment! Subscribe today via your favorite podcast app.
Focal Therapy Options for Prostate CancerAUA Urology Core Curriculum: auau.auanet.org/coreHost: Jay D. Raman, MD, FACS, FRCS(Glasg)Guest: Ruben Olivares, MDOutline:Segment 1: Why Focal Therapy?Segment 2: Patient selection for Focal TherapySegment 3: Review of Existing Focal Therapy ModalitiesSegment 4: How to Build a Successful Focal Therapy Program
Hereditary Kidney Cancer SyndromesCME Available: https://auau.auanet.org/node/41772ACKNOWLEDGEMENTS:Support provided by an independent educational grant from: Merck & Co., Inc. LEARNING OBJECTIVES:At the conclusion of this activity, participants should be able to:1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation.2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members.3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors.4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies.5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.
Prostate Cancer Update (2024): Expert Guidance for UrologistsCME Available: https://auau.auanet.org/node/41868AcknowledgementsSupport provided by independent educational grants from:AstellasLantheus Medical ImagingNovartis Pharmaceuticals CorporationPfizer, Inc.Learning ObjectivesAt the conclusion of this activity, the learner will:1. Align their practice with current AUA Guidelines (and recent amendments) pertaining to Screening, Diagnosis, and Management of Prostate Cancer.2. Determine appropriate use of biomarker testing as it relates to diagnosis and therapy.3. Analyze the role of imaging and types of imaging that aid in staging patients with prostate cancer.4. Implement appropriate treatment paradigms for metastatic prostate cancer including treatment intensification.5. Discuss the role of genetic and molecular profiling in the personalization of prostate cancer treatment plans.
Treatment Intensification in Metastatic HSPCCME Available: https://auau.auanet.org/node/41733ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
Appropriate Use of Genetic Testing (who, what, when and how?)CME Available: https://auau.auanet.org/node/41734ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.
Sequencing Of AgentsCME Available: https://auau.auanet.org/node/41735ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.
Urologic Oncology: Genetics And GenomicsAUA Urology Core Curriculum: auau.auanet.org/coreHost: Jay D. Raman, MD, FACS, FRCS(Glasg)Guest: Hong Truong, MD, MSOutline: Segment 1: Genetics 101 – How Genes Influence Cancer RiskSegment 2: Genetic Risk AssessmentSegment 3: Genetics of Kidney CancerSegment 4: Genetics of Upper Tract CancerSegment 5: Genetics of Prostate Cancer
Biomarkers and Molecular Imaging for Prostate CancerCME Available: https://auau.auanet.org/node/41727ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Lantheus Medical ImagingNovartis Pharmaceuticals CorporationLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.
Kidney Cancer & SBRT in the Management of RCCAUA Urology Core Curriculum: auau.auanet.org/coreHost: Jay D. Raman, MD, FACS, FRCS(Glasg)Guest: Daniel Shapiro, MDOutline:Segment 1: History of radiation therapy in renal cell carcinomaSegment 2: Radiation use in the setting of primary kidney tumorsSegment 3: Radiation use for locally advanced tumors including tumor thrombiSegment 4: Radiation therapy for metastatic diseaseSegment 5: Limitations of radiation therapy and selecting patients for radiation therapy
Pediatric Urology: Differences of Sex DevelopmentAUA Urology Core Curriculum: auau.auanet.org/coreHost: Jay D. Raman, MD, FACS, FRCS(Glasg)Guest: Emilie Johnson, MD, MPH, FACS, FAAPOutline:Segment 1: DSD Nomenclature – Words Matter!Segment 2: Multidisciplinary Care Model Segment 3: Example Conditions Segment 4: Approach to Prenatal and Early Postnatal Care Segment 5: Gonadal Management – also evolving
How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent CME Available: https://auau.auanet.org/node/41124At the conclusion of this activity, participants will be able to:1. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.2. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.3. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.4. Identify patients with radiorecurrent organ-confined prostate cancer.5. Identify those patients who are candidates for local therapy of oligometastatic disease in relapsing prostate cancer.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
The Changing Face of Advanced Prostate Cancer 2024CME Available: https://auau.auanet.org/node/41136At the conclusion of this activity, participants will be able to:1. Identify and treat a patient with newly diagnosed M1 prostate cancer with androgen deprivation therapy plus be able to offer novel ADT. Furthermore, recognize high-volume new M1 prostate cancer so as to be able to refer to a genitourinary medical oncologist for chemotherapy if necessary.2. Diagnose M0 CRPC, and be able to educate patients about using novel oral androgen receptor inhibitors added to traditional androgen deprivation therapy as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, understand the differences between these novel oral agents and educate patients about side effects and toxicities. Finally, understand the role or lack of role of prostate-specific membrane antigen PET in working up this disease state.3. Apply the latest phase III randomized controlled trial results for new therapies in M1 CRPC, and be able to educate their patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer.4. Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape, and for providers and teams to embrace the multidisciplinary nature of care for our patients.5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents and novel androgen receptor-targeted agents emerging in 2024.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Now in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24
Prostate Cancer Diagnosis: AUA Guidelines on use of PSA Biomarkers, MRI and Biopsy Techniques CME Available: https://auau.auanet.org/node/41113At the conclusion of this activity, participants will be able to:1. Apply the Early Detection of Prostate Cancer: AUA/SUO Guideline (2023), and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement.2. Identify how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically significant prostate cancer, while avoiding unnecessary biopsies and detection of clinically insignificant prostate cancers.3. Identify the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences.4. Identify available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use, and the clinical scenarios in which they are most valuable to be used.5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer and implement safe biopsy practices with respect to approach, avoidance of infection, and attention to patient comfort; understand the rationale for transperineal prostate biopsy and its technique; be able to establish a transperineal biopsy practice.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your PracticeCME Available: https://auau.auanet.org/node/41033At the conclusion of this activity, participants will be able to:1. Identify the research that led to the approval of genomic cancer for prostate cancer and the implementation of advanced imaging for prostate cancer.2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation.3. State the National Comprehensive Cancer Network Guidelines for genomic testing and advanced imaging for prostate cancer.4. Discern the different prognostic end points provided by various genomic tests.5. Recognize candidates for, and implications of, germline testing for prostate cancer.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUA2024: Upper Tract Urothelial Cancer (UTUC) GuidelinesUpper Tract Urothelial Cancer (UTUC) Guidelines – An Interactive and Evidence-Based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video PresentationCME Available: https://auau.auanet.org/node/41021At the conclusion of this activity, participants will be able to:1. Identify demographics, predisposing risks, hereditary factors, common terms.2. Describe workup, imaging, role of standardized endoscopic assessment, cytology and biopsy.3. Apply clinical features of disease risk, role of risk assessment and management options.4. Identify candidates for endo management, describe counseling/risks, safe approaches, troubleshooting.5. Explain setting and role for adjunctive chemotherapy use, importance of renal function, genetic counseling; describe approach to ureterectomy/bladder cuff, node dissection templates, intravesical therapy use; explain the rationale and use of risk-adjusted follow-up for endoscopy and imaging.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Merck & Co., Inc.
The Surgical Management of BPH and Updates from the AUA Clinical Guidelines Podcast (2024)CME Available: https://auau.auanet.org/node/41595ACKNOWLEDGEMENT:This educational series is supported by an independent educational grant from Olympus Corporation of the Americas.At the conclusion of this activity, participants will be able to: 1. Describe the role of the AUA Clinical Guideline on the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.4. Differentiate between each of the new technologies for treating BPH/LUTS based on both their mode-of-action and the quality of their supporting evidence.
New AUA Guideline (2024): Salvage Therapy for Prostate CancerCME Available: https://auau.auanet.org/node/41074At the conclusion of this activity, participants will be able to:1. Identify and effectively interpret the optimal timing of salvage radiation therapy following radical prostatectomy, considering the factors that can influence this decision in a clinical context.2. Develop an understanding of which patients should receive ADT alongside salvage radiation therapy following radical prostatectomy, and how to appropriately decide the duration of ADT for patients.3. Identify and analyze the use of risk stratification tools and next-generation imaging techniques for guiding treatment decisions and monitoring in patients with biochemical recurrence following primary therapy.4. Evaluate the role and benefits of advanced treatment options such as intensified systemic therapy and metastasis-directed therapy.5. Evaluate and understand the indications, efficacy, and potential complications of different salvage local therapies, such as salvage prostatectomy, radiotherapy and cryotherapy, for patients with local recurrence following primary radiation therapy.
AUA2024: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice CME Available: https://auau.auanet.org/node/40976At the conclusion of this activity, participants will be able to:1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing.2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability.3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer.4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common ProblemsCME Available: https://auau.auanet.org/node/41097At the conclusion of this activity, participants will be able to:1. Implement current practice guidelines and explain methods and resources to improve TURBT skills.2. Identify the best intravesical agent and duration of therapy for low-, intermediate- and high-risk NMIBC and what to do during a BCG shortage.3. Identify methods to treat significant toxicities from various intravesical therapies.4. Define high-risk scenarios that necessitate cystectomy and options for BCG-unresponsive disease.5. Identify the scientific rationale for investigating immune oncology agents for BCG-unresponsive disease and become familiar with current clinical trial designs.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Merck & Co., Inc.
AUA2024: Contemporary Pharmacotherapy for OAB 2024: Monotherapy and Combined Pharmacotherapy to Optimize TreatmentCME Available: https://auau.auanet.org/node/41048At the conclusion of this activity, participants will be able to:1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents5. Discuss potential future pharmacological pathways and therapies for OAB.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas
AUA2024: AUA Advanced Prostate Cancer Guidelines CME Available: https://auau.auanet.org/node/41027At the conclusion of this activity, participants will be able to:1. Identify appropriate use of genetic testing and genetic counseling.2. Identify appropriate use of somatic testing and treatments related to specific genetic alterations.3. Identify appropriate combination therapy with androgen deprivation therapy plus novel androgen access therapies and chemotherapy. Early treatment intensification will be discussed in metastatic hormone-sensitive prostate cancer.4. Identify the treatments for nonmetastatic CRPC and oncologic outcomes based on AUA/SUO (Society of Urologic Oncology) Guidelines.5. Cancel patients on available treatment options for CRPC as well as combination therapy and sequencing based on AUA/SUO Guidelines.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Live from AUA2024: Highlights in Bladder CancerCME Available: https://auau.auanet.org/node/41085At the conclusion of this activity, participants will be able to:1. Discuss the newly released amendment to the AUA/SUO Guideline on Non-Muscle Invasive Bladder Cancer.2. Describe recent developments in the management of non-muscle invasive bladder cancer.3. Review current management approaches for non-metastatic muscle-invasive bladder cancer.4. Identify novel therapies and their mechanism of action in the management of advanced bladder cancer.ACKNOWLEDGEMENTThis educational activity is supported by independent educational grant from:Merck & Co., Inc.
AUA2024: Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management CME Available: https://auau.auanet.org/node/41040At the conclusion of this activity, participants will be able to:1. Identify clinically available data that can help assess risk of UTUC disease.2. Verbalize the important role of kidney function before and after nephroureterectomy in the management of UTUC, and calculate the estimated new baseline glomerular filtration rate.3. Compare the clinical trial data on intravesical, neoadjuvant and adjuvant chemotherapy.4. Recognize the possibility of an undiagnosed inheritable syndrome in patients with UTUC, ask about history of nongenitourinary cancers, and identify the clinical methods for screening and diagnosis of inheritable syndromes.5. Recognize the importance of preoperative chemotherapy and response-based surgical management for locoregional nodal recurrence after nephroureterectomy.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Merck & Co., Inc., UroGen Pharma, Inc.
AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice ProviderCME Available: https://auau.auanet.org/node/41048At the conclusion of this activity, participants will be able to:1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents5. Discuss potential future pharmacological pathways and therapies for OAB.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas
Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) Webcast (2024)CME Available: https://auau.auanet.org/node/41056At the conclusion of this activity, participants will be able to:1. Discuss the third-line therapies available to treat OAB refractory to conservative techniques.2. Effectively provide counseling regarding advanced treatment techniques with "friendly, nonthreatening" language that does not intimidate the patients.3. Consider helpful techniques to optimize lead placement for sacral neuromodulation and be comfortable with troubleshooting the device.4. Incorporate caveats that are important in the delivery of injections in the bladder for treatment of OAB. 5. Incorporate peripheral nerve stimulation options, including the traditional and newer techniques that will be discuss in detail, into their practice as they see fit. ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas
AUA2024: 003IC Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical PracticeCME Available: https://auau.auanet.org/node/40976At the conclusion of this activity, participants will be able to:1. Describe key components of genetic risk assessment, genetic counseling and informed consent for genetic testing.2. Identify elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers and clinical actionability.3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic result in prostate cancer screening and management of both localized and advanced prostate cancer.4. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome, and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Journal Club 101Guest: Melissa Kaufman, MD, PHD, FACSOutline:Segment #1: History of peer reviewSegment #2: Models of peer reviewSegment #3: General review best practicesSegment #4: General structure for manuscript reviewSegment #5: Granular aspects of manuscript review
BPH: Surgical TreatmentGuest: Bilal Chughtai, MDOutline:Segment #1: Bladder HealthSegment #2: DiagnosticsSegment #3: StentsSegment #4: New MISTs
AUA2024: Surgical Laser Enucleation of the ProstateGuests: Amy Krambeck, MD and Mark Assmus, MDOutline:Segment #1: Why EnucleationSegment #2: What makes this course special?Segment #3: What is new this year compared to last year?Segment #4: What do you think makes this course unique?Segment #5: Who is the ideal participant?
AUA2024: A Specialized Masterclass for Single-port Robot-Assisted SurgeryGuests: Simone Crivellaro, MD and Ahmed Ghazi MD, MHPEOutline:Segment #1 Topic: The need for ongoing surgical education given the rise in introduction of new technologies in urology.Segment #2 Topic: Current status of Hands-on skills courses in UrologySegment #3 Topic: History of hands on courses offered at AUASegment #4 Topic: Educational approach for surgical trainingSegment #5 Topic: Single-port masterclass at AUA a step in a new direction
Update Series (2024) Lesson 1: A Case-Based Discussion of Priapism GuidelinesNow in its 43rd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update24
AUA2023 Take Home Messages Part 5Take Home Messages: Take Home Messages: BPH/LUTSSpeaker: Dr. Dean EltermanTake Home Messages: ImagingSpeaker: Dr. Richard MatulewiczTake Home Messages: Robotic SurgerySpeaker: Dr. Andrew HungTake Home Messages: Surgical EducationSpeaker: Dr. Simone Thavaseelan
AUA2023 Take Home Messages Part 4Take Home Messages: Increasing Representation in UrologySpeaker: Dr Larissa BreslerTake Home Messages: Healthcare DisparitiesSpeaker: Dr. Adam MurphyTake Home Messages: TransplantationSpeaker: Dr. Jason LeeTake Home Messages: Female Urology/IncontinenceSpeaker: Dr. Yahir Santiago-Lastra
AUA2023 Take Home Messages Part 3Take Home Messages: Infertility/AndrologySpeaker: Dr. Joshua HalpernTake Home Messages: Sexual DysfunctionSpeaker: Dr. Peter TsambarlisTake Home Messages: PediatricsSpeaker: Dr. Kate KraftTake Home Messages: Global Health/HumanitarianSpeaker: Dr. Rajiv Singal
AUA2023 Take Home Messages Part 2Take Home Messages: Basic Science (Benign)Speaker: Dr. Douglas StrandTake Home Messages: ReconstructionSpeaker: Dr. Jessica DeLongTake Home Messages: Endourology/StonesSpeaker: Dr. Noah CanvasserTake Home Messages: Infection/InflammationSpeaker: Dr. Chris Doiron
AUA2023 Take Home Messages Part 1Take Home Messages: Basic Science (Malignant)Speaker: Dr. Douglas ScherrTake Home Messages: Kidney CancerSpeaker: Dr. Amy LuckenbaughTake Home Messages: Bladder CancerSpeaker: Dr. Jennifer TaylorTake Home Messages: Prostate CancerSpeaker: Dr. Samuel Washington
PARPi: Management of Adverse Events (2024)CME Available: https://auau.auanet.org/node/39609Release Date: January, 2024Expiration Date: January, 2025LEARNING OBJECTIVES:1. Identify approved PARPi for prostate cancer and patients who may benefit from PARPi based therapy.2. Evaluate available clinical safety and efficacy data for PARPi.3. Describe indications and contraindications for PARPi in patients with advanced prostate cancer.4. Identify how to manage adverse events that patients may experience while taking a PARPi.ACKNOWLEDGEMENTS:This educational activity is supported by an independent educational grant from:Pfizer, Inc.
AUA2023 Journal of Urology Lecture: Surgery Harms Surgeons. What can we do?Speaker: Dr. Kevin Turner
AUA2023 Ramon Guiteras Lecture: The Complicated Decisions Required to Eliminate Never EventsSpeaker: Dr Louis Kavoussi, Smith Institute For Urology.
AUA2023 John Duckett Memorial Lecture: Innovation by Necessity: Improving Urodynamics for Children with Spina BifidaSpeaker: Dr. Johnathan Routh, Chief of Children's Surgery, Duke University School of Medicine.
AUA2023 John K. Lattimer Lecture: Innovation in Urology: From a Seminal “Why” to a Functional “How”Speaker: Dr. Ralph Clayman, Distinguished Professor / Endowed Chair in Endourology, University of California, Irvine.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer CME Available: https://auau.auanet.org/node/39542Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment.2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches.3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up.ACKNOWLEDGEMENTS:Support provided by independent educational grants from: AstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:The Latest Breakthroughs in Immunotherapy for GU CancersCME Available: https://auau.auanet.org/node/39543Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers.ACKNOWLEDGEMENTS:Support provided by independent educational grants from: AstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer CME Available: auau.auanet.org/node/39487Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Identify the indications for germline testing in prostate cancer patients.2. Explain how germline testing is used to identify genetic mutations in genitourinary (GU) cancers, specifically focusing on prostate cancer.3. Analyze the potential advantages and challenges associated with using germline testing and targeted therapies in the management of prostate cancer.ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Astellas and Pfizer, IncAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:Novel Imaging for Genitourinary Cancers - Diagnostics and TheranosticsCME Available: https://auau.auanet.org/node/39411Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Review the latest clinical trials investigating the use of PET imaging agents in prostate, kidney, and urothelial cancer, including their diagnostic accuracy and impact on patient management.2. Discuss the available PET imaging agents for prostate cancer, with a specific focus on PSMA (Prostate-Specific Membrane Antigen) PET imaging, including its mechanism of action and its potential for detection of primary tumors, lymph node metastases, and distant metastases.3. Discuss the benefits of incorporating PET imaging, including PSMA PET, in guiding treatment decisions for GU cancers, such as its impact on treatment selection, treatment response assessment, and the potential for theranostic approaches.ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Astellas and Pfizer, IncAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)CME Available: https://auau.auanet.org/node/39410Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Discuss the potential benefits, limitations, and controversies associated with prostate cancer screening.2. Summarize the key recommendations provided in the AUA/SUO Guideline regarding early detection strategies for prostate cancer.3. Analyze the implications of the AUA/SUO Guideline on clinical practice, shared decision-making, and patient counseling regarding early detection of prostate cancer.ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Astellas and PfizerAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer CME Available: https://auau.auanet.org/node/39374Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC.2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions.3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials.ACKNOWLEDGEMENTS:Support provided by independent educational grants from: AstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.
PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test (2023)CME Available: https://auau.auanet.org/node/39603Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVES:At the conclusion of this activity, the learner will be able to:1. Review recommended criteria for genetic testing of prostate cancer patients, currently available gene panels, and options for testing these men.2. Explain the importance of testing for germline and somatic mutations and their implications for utilizing PARPi.3. Describe work flows for genetic testing and utilization of genetic counselors.4. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing for patients and their families.ACKNOWLEDGEMENTThis educational activity is supported by an independent educational grant from Pfizer, Inc.
Infectious Complications Following Prostate Biopsy: Strategies for Reducing Infections and Reducing Health Care CostsCME Available: https://auau.auanet.org/node/39485Release Date: December, 2023Expiration Date: December, 2024LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Describe health care costs associated with prostate biopsy infections.2. Identify the steps where modifications in technique can reduce the risk of complications.3. Apply modified technique at various steps of the procedures to mitigate the risk of complications.ACKNOWLEDGEMENTProject Firstline is a national collaborative led by the U.S. Centers for Disease Control and Prevention (CDC) to provide infection control training and education to frontline health care workers and public health personnel. AMA has partnered with Project Firstline, as supported through Cooperative Agreement CDC-RFA-CK20-2003. The American Urological Association is proud to collaborate with AMA and Project Firstline in this educational activity. CDC is an agency within the Department of Health and Human Services (HHS). The contents of this event do not necessarily represent the policies of CDC or HHS and should not be considered an endorsement by the Federal Government.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:Germline Testing in GU Cancers – How I Do It CME Available: https://auau.auanet.org/node/39544Release Date: December, 2023Expiration Date: December, 2024ACKNOWLEDGEMENTS:Support provided by independent educational grants from: AstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.LEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Differentiate between germline and somatic testing in the context of GU cancers, understanding the fundamental differences in the types of genetic alterations detected and their implications for patients and their families.2. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing.3. Evaluate the clinical significance and impact of germline testing results on treatment decisions, surveillance recommendations, and family management.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:Treatment Intensification for Advanced Prostate CancerCME Available: https://auau.auanet.org/node/39486Release Date: November, 2023Expiration Date: November, 2024LEARNING OBJECTIVES:At the conclusion of these activities, participants will be able to:1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations. 2. Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy. 3. Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection.ACKNOWLEDGEMENTS:Support provided by independent educational grants from: Astellas and Pfizer, Inc.AstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.REFERENCES:Freedland SJ, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evidence. 2023.Smith MR, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022.Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022.Clarke NW, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022Chi KN, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023.Agarwal N, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023.
PARPi: Precision Medicine in Advanced Prostate Cancer (2023)CME Available: https://auau.auanet.org/node/39597Release Date: November, 2023Expiration Date: November, 2024At the conclusion of this activity, the learner will be able to:1. Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class.2. Describe the role of PARPi treatment alone and in combination with other cancer based therapies.3. Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors.4. Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.ACKNOWLEDGEMENTThis educational activity is supported by an independent educational grant from:Pfizer, Inc.
Prostate Cancer Treatment IntensificationModerator: Dr. Jay D. RamanGuest: Dr. Michael S. Cookson Acknowledgement: This podcast was funded by and in collaboration with AZ. All opinions are that of the faculty and do not necessarily reflect those of AstraZeneca. Release Date: 11/8/2023Expiration Date: 11/8/2024
Update Series (2023) Lesson 33: A Critical Appraisal of the 2021 AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract DysfunctionNow in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23
Disparities in Care and Barriers to Access for Patients with Advanced Prostate CancerCME Available: https://auau.auanet.org/node/39088Release Date: October, 2023Expiration Date: October, 2024At the conclusion of these activities, participants will be able to:1. Recognize current patterns of use for systemic therapies in patients with advanced prostate cancer.2. Identify disparities in access to care with respect to advanced prostate cancer treatment (ie. race, geography, socioeconomics).3. Understand opportunities to improve quality and compliance with ADT treatment across different treatment populations.4. Appreciate financial challenges that may be associated with current therapy options for advanced prostate cancer.5. Apply treatment approaches that improve patient adherence to ADT including use of oral and parenteral therapies.ACKNOWLEDGEMENTS:This series is supported by independent educational grants from: Myovant Sciences LTDPfizer, Inc.REFERENCES:Benjamin, D.J., Shrestha, A., Fellman, D. et al. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry. Prostate Cancer Prostatic Dis (2023). https://doi.org/10.1038/s41391-023-00732-9Cortese BD, Dusetzina SB, Al Hussein Al Awamlh B, Penson DF, Chang SS, Barocas DA, Luckenbaugh AN, Scarpato KR, Moses KA, Talwar R. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer. Urol Pract. 2023 Sep;10(5):476-483. doi: 10.1097/UPJ.0000000000000425. Epub 2023 Jul 3. PMID: 37409930.
Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side EffectsCME Available: https://auau.auanet.org/node/39087Release Date: October, 2023Expiration Date: October, 2024At the conclusion of these activities, participants will be able to:1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy.2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health, and metabolic risk.3. Recognize strategies to monitor and manage side effects of ADT and novel hormonal treatments.4. Understand adverse effects of newer agents for advanced prostate cancer including PARP inhibitors, immunotherapy, and theranostics.5. Review management options for adverse effects of newer agents for advanced prostate cancer.This series is supported by independent educational grants from: Myovant Sciences LTDPfizer, Inc.REFERENCES:1. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011;306:2359-2366.2. NCCN Guidelines for prostate cancer. Version 4.2023. www.nccn.org3. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082-1090.
Genetic Testing and Stone DiseaseCo-host: Kyle Wood, MDPopulation analysis demonstrated that genetic conditions resulting in stone disease are magnitudes higher than those seen in clinical cohorts, suggesting underdiagnosis. Urologist play a unique role as we often times have many touch points with these patient given their presentation for stone disease. With the advancement of treatments, specifically in primary hyperoxaluria, it is essential that urologist play a more active role in the earlier diagnosis of patients. Genetic testing has become readily available at lower cost and much of the perceived barriers to genetic testing are addressed by current available programs. Outline:1. The contribution of genetics to kidney stone disease2. Specific studies using genetic testing3. Primary Hyperoxaluria as an example4. Current Genetic Testing and Ease5. The role of the UrologistReferences:- Hill AJ, Basourakos SP, Lewicki P, et al. Incidence of kidney stones in the United States: The Continuous National Health and Nutrition Examination Survey. J Urol. 2022;207(4):851-856.- Singh P, Harris PC, Sas DJ, Lieske JC. The genetics of kidney stone disease and nephrocalcinosis. Nat Rev Nephrol. 2022;18(4):224-240.- Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int. 2005;67(3):1053-1061.- Daga A, Majmundar AJ, Braun DA, et al. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney Int. 2018;93(1):204-213.- Braun DA, Lawson JA, Gee HY, et al. Prevalence of monogenic causes in pediatric patients with nephrolithiasis or nephrocalcinosis. Clin J Am Soc Nephrol. 2016;11(4):664-672.- Halbritter J, Baum M, Hynes AM, et al. Fourteen monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol. 2015;26(3):543-551.- Knoers N, Antignac C, Bergmann C, et al. Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrol Dial Transplant. 2022;37(2):239-254.- Groothoff JW, Metry E, Deesker L, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol. 2023;19(3):194-211.- van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant. 2012;27(10):3855-3862.- Hopp K, Cogal AG, Bergstralh EJ, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol. 2015;26(10):2559-2570.- Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216-1226.- Baum MA, Langman C, Cochat P, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2023;103(1):207-217.- Soliman NA, Nabhan MM, Abdelrahman SM, et al. Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center. Nephrol Ther. 2017;13(3):176-182.- Schonauer R, Scherer L, Nemitz-Kliemchen M, et al. Systematic assessment of monogenic etiology in adult-onset kidney stone formers undergoing urological intervention-evidence for genetic pretest probability. Am J Med Genet C Semin Med Genet. 2022;190(3):279-288.
Advances in ADT Part II: A Guide for UrologistsCME Available: https://auau.auanet.org/node/39385Release Date: October, 2023Expiration Date: October, 2024LEARNING OBJECTIVESAfter participating in this educational activity, participants will be able to:1. Recognize and characterize different disease states for advance prostate cancer including M0 HSPC, M1 HSPC, M0 CRPC, and M1 CRPC.2. Discuss the role of a multidisciplinary shared team approach for the diagnosis and management of advanced prostate cancer.3. Facilitate discussions with patients and caregivers regarding treatment intensification for advanced prostate cancer.4. Identify the role of combination therapy with ADT and additional systemic therapy to yield optimal survival outcomes for metastatic prostate cancer.5. Differentiate mechanisms of action and side effects when ADT is delivered via GnRH agonists vs. antagonists.ACKNOWLEDGEMENTSIndependent educational grant support provided by:Myovant Sciences LTDPfizer, Inc.
Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into PracticeCME Available: https://auau.auanet.org/node/39292Release Date: September, 2023Expiration Date: September, 2024After participating in this educational activity, participants will be able to:1. Cite recommendations within the newly amended AUA/SUO Advanced Prostate Cancer Guideline.2. Assess the impact of newly approved agents on the management of men with Advanced Prostate Cancer.3. Define M0 CRPC and the treatment options.4. Identify clinically meaningful endpoints in clinical trials of patients with M0 CRPC.5. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.6. Discuss treatment intensification in mHSPC.7. Discuss challenges in incorporating AUA/SUO Advanced Prostate Cancer Guideline and management of advanced mHSPC and CRPC into community practice.ACKNOWLEDGEMENTSThis educational series is supported by independent educational grants from: •Astellas and Pfizer, Inc.•Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC•Lantheus Medical Imaging•Merck & Co., Inc.•Pfizer, Inc.
AUA2023: Managing Toxicities of Checkpoint Inhibitors: A Urologist’s GuideCME Available: https://auau.auanet.org/node/38322CME Expiration Date: May, 2024ACKNOWLEDGEMENTSIndependent educational grant support provided by:AstellasAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCLantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc.
AUA2023: How to use PSMA-PET/CT in the Management of Relapsing Prostate Cancer Patients following Local Therapy with Curative Intent CME Available: https://auau.auanet.org/node/38312CME Expiration Date: May, 2024ACKNOWLEDGEMENTSIndependent educational grant support provided by:AstellasAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCLantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc.
Treatment for Hormone Sensitive Prostate Cancer
CME Available: https://auau.auanet.org/node/38703
Treatment for Hormone Sensitive Prostate Cancer (2023), is an exciting new educational offering to update urologists on the latest advancements in the management of hormone sensitive prostate cancer (HSPC), including treatment intensification. This educational initiative is comprised of multiple formats, including a live virtual course, on-demand webcast, and a podcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion.
At the conclusion of this activity, participants will be able to: 1. Apply the AUA Clinical Guidelines for Advanced Prostate Cancer for the treatment of HSPC. 2. Summarize the current utilization of treatment intensification in HSCP and apply appropriate treatment intensification in men with HSPC. 3. Describe the current indications, potential benefits and adverse events that may occur with use of doublet and triplet regimens as compared to SOC in HSPC. 4. Identify opportunities for shared care and team-based approaches to offer state-of-the-art evidenced care for HSPC. 5. Facilitate discussions with patients and caregivers to engage them in the HSPC treatment plan.
ACKNOWLEDGEMENT This educational activity is supported by an independent educational grant from: Astellas Pfizer, Inc.
Update Series (2023) Lesson 21: Management of Chronic Pelvic Pain in Men
Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.
For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23
AUA2023: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider
CME Available: https://auau.auanet.org/node/38307 CME Expiration Date: May, 2024
ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.
AUA2023: Upper-Tract Urothelial Cancer Guidelines: An Interactive and Evidence-based Course Highlighting the Full Spectrum of Disease via Case Discussion and Video Presentation
CME Available: https://auau.auanet.org/node/38327 CME Expiration Date: May, 2024
ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Merck & Co., Inc. Pfizer, Inc.
AUA2023: What the General Urologist Should Know about Care of Transgender Patients
CME Available: https://auau.auanet.org/node/38342 CME Expiration Date: May, 2024
ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.
AUA2023: Refractory Overactive Bladder: How To Select 3rd Line Therapies and Optimize Outcomes
CME Available: https://auau.auanet.org/node/38287 CME Expiration Date: May, 2024
ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas Urovant Sciences, Inc.
AUA2023: Prostate Cancer Diagnosis
CME Available: https://auau.auanet.org/node/38302 CME Expiration Date: May, 2024
ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.
Based on the findings from the 2022 AUA global survey and needs assessment in bladder cancer, the AUA has developed this new series of virtual courses to update urologists on the latest advancements in bladder cancer care. This course will address new and emerging treatment options for non‐muscle invasive (NMIBC) and muscle‐invasive bladder cancer (MIBC) with a focus on identifying side effects and interventions, review of guidelines specific to first and second line therapies, timing and usage of neoadjuvant and adjuvant systemic therapy, BCG shortage and the urologists role in clinical trial enrollment. Currently available agents as well as those in development will be discussed.
CME Available: https://auau.auanet.org/node/38615
ACKNOWLEDGEMENTS This educational series is supported by an independent educational grant from AstraZeneca.
After participating in this educational series, participants will be able to: 1. Delineate key factors to risk stratify patients with NMIBC and MIBC. 2. Review guidelines focused on first‐ and second‐line therapies for NMIBC and MIBC. 3. Describe emerging treatment options with intravesical and systemic therapies for patients in an era of BCG shortage and for patients with BCG unresponsive disease and determine the appropriate timing and use of neoadjuvant and adjuvant systemic therapy for invasive bladder cancer. 4. Identify side effects and possible interventions to ameliorate side effects for these therapies. 5. Recognize the urologist’s role in clinical trials and how to overcome obstacles to clinical trial enrollment.
AUA2023: Advancing Gender Equity in Urology: Allyship for Men and Advocacy for Women
CME Available: https://auau.auanet.org/node/38337/
ACKNOWLEDGEMENTS Independent educational grant support provided by: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc.
AUA2023: Genetics and Genomics of GU Malignancies: Applications into Your Clinical Practice
CME Available: https://auau.auanet.org/node/38317
ACKNOWLEDGEMENTS Independent educational grant support provided by: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc.
AUA2023: AUA Guidelines on Advanced Prostate CancerCME Available: https://auau.auanet.org/node/38297ACKNOWLEDGEMENTSIndependent educational grant support provided by:AstellasAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCLantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc.
AUA2023: Diversity, Equity and Inclusion in Urology: What Do We Need to KnowCME Available: https://auau.auanet.org/node/38332/ACKNOWLEDGEMENTSIndependent educational grant support provided by:AstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCMerck & Co., Inc.
AUA2023: The Changing Face of Advanced Prostate CancerCME Available: https://auau.auanet.org/node/38292ACKNOWLEDGEMENTSIndependent educational grant support provided by:AstellasAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCLantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc.
AUA2023: Contemporary Pharmacotherapy for OAB 2023CME Available: https://auau.auanet.org/node/38282ACKNOWLEDGEMENTSIndependent educational grant support provided by:AstellasUrovant Sciences, Inc.LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Define the similarities and differences between the various oral pharmacotherapies for OAB.2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta3 agonists and combination therapy.3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.5. Discuss potential future pharmacological pathways and therapies for OAB.
Live from AUA2023: Highlights in BPH is a panel discussion filmed during the 2023 AUA Annual Meeting!This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with BPH.CME Available: https://auau.auanet.org/node/38008ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Cook Medical, LLC.Olympus Corporation of the Americas
Live from AUA2023: Highlights in Advanced Prostate Cancer is a panel discussion filmed during the 2023 AUA Annual Meeting!CME Available: https://auau.auanet.org/node/38002This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with advanced prostate cancer. Faculty will review the latest advances in prostate cancer including the many new FDA-approved agents, as well as existing standard therapies. Urologists will gain the ability to translate the latest scientific advances into their routine clinical practice, improving the care of men with advanced prostate cancer.At the conclusion of the activity, participants will be able to:1. Describe recent developments in the medical management of advanced prostate cancer.2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.3. Discuss clinical investigations in the treatment of advanced prostate cancer.4. Analyze the risks and benefits of treatment for advanced prostate cancer.5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.ACKNOWLEDGEMENTSThis educational activity is supported by independent educational grants from:Astellas and Pfizer, Inc.AstraZenecaMerck & Co., Inc.
Complications of Vaginal MeshCourse Director: Kamran Sajadi, MDCourse Faculty:Farzeen Firoozi, MDChristopher F. Tenggardjaja, MD
AUA Urology Core Curriculum: auau.auanet.org/coreHost: Jay D. Raman, MD, FACSCo-Host: Sean Elliott, MDOutline:1. Are the terms “transitional urology” and “adult congenital urology” synonymous2. What are the unique challenges in transitional urology3. Why does spina bifida seem to dominate the transitional urology landscape4. Exstrophy5. Counseling pregnant women with a congenital urological condition6. How does posterior urethral valve bladder present in adulthood
Update Series (2023) Lesson 4: Difficult Foleys and Foley DifficultiesNow in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information, please visit the AUA Update Series on the AUAUniversity: https://auau.auanet.org/update23
AUA2022: Evaluation and Management of PriapismCourse Director: Martin Gross, MDCourse Faculty:Trinity J. Bivalacqua MD, PhDJay Simhan, MD, FACSFaysal A. Yafi, MD, FRCSC
This episode is brought to you by the AUA Leadership & Business Podcast Subscribe today by searching “AUA Leadership & Business” on your favorite podcast app.Host: Jennifer Miles-Thomas, MD, FPMRS Guest: Jaspreet S. Sandhu, MD
Modernizing Urology Care: The Current and Future State of Virtual Care in the United StatesHost: Jay D. Raman, MD, FACSGuest: Chad Ellimoottil, MD, MS
Health Equities and Variations in Advanced Prostate Cancer CareCME Available: https://auau.auanet.org/node/37728LEARNING OBJECTIVES:At the conclusion of these activities, participants will be able to:1. Identify the impact of race and cultural barriers for ethnic minorities on medical clinical care specific to advanced prostate cancer.2. Evaluate financial toxicity as a barrier to optimal patient care specific to advanced prostate cancer.3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations.ACKNOWLEDGEMENTS:This series is supported by independent educational grants from: Myovant Sciences LTDPfizer, Inc.
Comorbid Conditions in the Patient with Advanced Prostate CancerCME Available: https://auau.auanet.org/node/37727 LEARNING OBJECTIVES:At the conclusion of these activities, participants will be able to:1. Oversee comorbidities and describe their management in the context of advanced prostate cancer treatment.2. Assess the potential cardiovascular risk associated with ADT.3. Differentiate the roles of the urologist, other specialists and advanced practice providers and identify opportunities for shared care and team-based approaches of patients with prostate cancer.ACKNOWLEDGEMENTS:This series is supported by independent educational grants from: Myovant Sciences LTDPfizer, Inc.
Advances in ADT: A Guide for Urologists and APPsCME Available: https://auau.auanet.org/node/37866At the conclusion of this activity, participants will be able to:1. Identify and treat a patient with new diagnosed M1 prostate cancer with ADT plus be able to offer additional therapies that extend survival.2. Analyze the risks and benefits of treatment for M1 HSPC, MO CRPC, and M1 CRPC. 3. Differentiate the clinical significance of GnRH agonists vs. GnRH antagonists and newer treatments that complement these options.4. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer.5. Facilitate discussions with patients and caregivers regarding ADT and advanced prostate cancer treatment. ACKNOWLEDGEMENTSIndependent educational grant support provided by:Myovant Sciences LTDPfizer Inc.
AUA2022 JU Lecture: Engaging Patients: A Challenge to our Care Delivery and Research PrioritiesSpeaker: Angela Smith, MD, MSUniversity of North Carolina at Chapel Hill
AUA2022 Ramon Guiteras Lecture: How to Reach Excellence in Urology: Challenges and OpportunitiesSpeaker: Francesco Montorsi, MD
AUA2022 John Duckett Memorial Lecture: Lifelong Learning, What’s in it for me?Speaker: David Joseph, MDProfessor of Urology / Vice Chair Academic Affairs / Beverly P. Head Chair in Pediatric Urology at Children's of AlabamaChildren's of Alabama
AUA2022 John K. Lattimer Lecture: Testosterone, Science and Human DignitySpeaker: Abraham Morgentaler, MD, FACS
AUA2022 Presidential AddressSpeaker: Raju Thomas, MD, FACS, FRCS, MHAUrology Chair, Tulane University Medical Center and AUA PresidentTulane University
PARP Inhibitors in Advanced Prostate Cancer Care PodcastCME Available: https://auau.auanet.org/node/37321Host: Jay D. Raman, MD, FACSGuests: Maha Hussain, MD and Ganesh Raj, MD, PhDLEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.ACKNOWLEDGEMENTS:This series is supported by independent educational grants from:AstellasAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCLantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc.Sanofi Genzyme
Advancing Women in Urology: Sponsorship and It’s Role in Career Advancement in MedicineHost: Jay D. Raman, MD, FACSGuest: Peggy Pearle, MD and Simone Thavaseelan, MDOutline: Segment #1 Defining Sponsorship Segment #2 Role in Career Advancement/Importance Segment #3 Identifying the IssueSegment #4 Key Characteristics of healthy/effective Sponsorship Segment #5 Opportunities for Action ACKNOWLEDGEMENTThis educational series was made possible by support from UrovantResources:Jain, S. Why Sponsorship in Medicine Matters. Wolters Kluwer Health, https://www.wolterskluwer.com/en/expert-insights/why-sponsorship-in-medicine-matters (2020). Ayyala, M.S., et al. Mentorship Is Not Enough: Exploring Sponsorship and Its Role in Career Advancement in Academic Medicine. Acad Med. 94, 94-100 (2019). Lewiss R.E., et al. Is Academic Medicine Making Mid-Career Women Physicians Invisible? J Womens Health (Larchmt). 29,187-192 (2020). Tesch, B.J., Wood, H.M., Helwig, A.L., Nattinger, A.B. Promotion of women physicians in academic medicine. Glass ceiling or sticky floor? JAMA. 273,1022-5 (1995).Silva, C. Study: Women Get Fewer Game Changing Leadership Roles. Harvard Business Review, https://hbr.org/2012/11/study-women-get-fewer-game-changingHewlett, S.A., Peraino, K., Sherbin, L., Sumberg, K. The Sponsor Effect: Breaking Through the Last Glass Ceiling. Boston, Mass Harvard Business Review (2011).Richter, K.P., et al. Women Physicians and Promotion in Academic Medicine. N Engl J Med. 383, 2148-2157 (2020). Foust-Cummings H. Sponsoring Women to Success. Catalyst, http://www.catalyst.org/system/files/sponsoring_women_to_success.pdf. (2011) Velez, D., et al. Rising Tides: Challenges and Opportunities for Women in the Urologic Workforce. Urology. 150, 47-53 (2021). Harris, C. How to find the person who can help you get ahead at work. TEDWomen, https://www.youtube.com/watch?v=gpE_W50OTUc.(2018). Penaloza NG,, et al. Someone Like Me: An Examination of the Importance of Race-Concordant Mentorship in Urology. Urology. 22. (2022) Butler, P.D. When excellence is still not enough. Am J Surg. 220, 543-544 (2020)
Addressing Disparities and Variations in Care in GU OncologyCME Available: auau.auanet.org/node/37337Host: Jay D. Raman, MD, FACSGuests: Kelvin Moses, MD, PhD and Svetlana Avulova, MDLEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Discuss the impact of race and cultural barriers on optimal GU cancer care.2. Evaluate financial toxicity as a barrier to optimal patient care in urologic cancer.3. Incorporate culturally sensitive communications to ensure quality care and reduce biases across diverse patient populations.ACKNOWLEDGEMENTS:This series is supported by independent educational grants from:AstellasAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCLantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc.Sanofi Genzyme
Advancing Women in Urology: Coaching and Self-AdvocacyHost: Jay D. Raman, MD, FACSGuest: Dr. Nancy SpectorAt the conclusion of this activity, participants will be able to:1. Describe the importance of working with a coach for career advancement and personal growth.2. List strategies to obtain coaching. 3. Define key attributes of a healthy and effective coaching relationship. ACKNOWLEDGEMENTThis educational series was made possible by support from UrovantResources:Institute of CoachingMcLean, Affiliate of Harvard Medical School https://instituteofcoaching.org/coaching-overview/coaching-benefits#:~:text=The%20benefits%20of%20coaching%20are,(source%3A%20ICF%202009International Coaching Federationhttps://coachingfederation.org/blog/what-makes-a-great-coachForbeshttps://www.forbes.com/sites/forbescoachescouncil/2018/04/24/your-no-fail-guide-to-selecting-an-executive-coach/?sh=85c2cd611e5c
Advancing Women in Urology: Negotiating for Success (2022)Advancing Women in Urology, an exciting new educational initiative, has been designed to elevate awareness and provide content that focuses on career tips, advancement, and education featuring women leaders in all areas of urology. The topic for this live course was based on feedback from an AUA survey and a women-led Steering Committee. Dr. Nancy Spector, Executive Director of Executive Leadership in Academic Medicine (ELAM), will moderate an engaging multi-disciplinary panel of three subject matter experts in an interview-style presentation and discussion. This 1-hour, conversation-style webinar will focus on the topic of Negotiation and includes what to consider when negotiating, negotiation strategies, and the impact of not negotiating. LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:1. Develop a framework for understanding the importance effective negotiation and self-advocacy has on the advancement of women.2. Identify negotiation strategies that can be applied to negotiations.3. Describe the impact negotiation has on the individual, the institution, and to the field.ACKNOWLEDGEMENTThis educational series was made possible by support from Urovant
Advanced Kidney Cancer: A Guide to Targeted Agents and ImmunotherapiesCME Available: https://auau.auanet.org/node/37329Host: Jay D. Raman, MD, FACSCo-Hosts: Monika Joshi, MD, MBBS and Brian Matthew Shuch, MDLEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to1. Discuss the current targeted and immunotherapy options available for the treatment of RCC.2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.3. Describe best practices in RCC patient selection for treatment options.4. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.ACKNOWLEDGEMENTS:This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc. Sanofi Genzyme
Advancing Women in Urology: The Importance of Meaningful MentorshipHost: Jay D. Raman, MD, FACSGuests: Anne M. Suskind, MD, MS, FACS, FPMRS and Stacy T. Tanaka, MD, MSOutline:1. What are the characteristics of a successful mentor or mentee2. Importance of mentorship for career advancement and personal growth3. Key characteristics of a healthy/effective relationship4. Strategies to build effective relationships5. Why women physicians have difficulty accessing mentors6. Addressing barriers to acting as a mentor
Urothelial Carcinoma: Advances in Immuno-OncologyHost: Jay D. Raman, MD, FACSCo-Hosts: Andrea Apolo, MD and Sima Porten, MDCME Available: auau.auanet.org/node/37325At the conclusion of this activity, participants will be able to1. Determine the pros/cons of sequencing strategies with chemotherapy and immunotherapy in first line metastatic urothelial carcinoma.2. Prioritize treatment options in first line metastatic urothelial carcinoma.3. Evaluate second line options for metastatic urothelial carcinoma.ACKNOWLEDGEMENTS:This series is supported by independent educational grants from:AstellasAstraZenecaJanssen Biotech, Inc., administered by Janssen Scientific Affairs, LLCLantheus Medical ImagingMerck & Co., Inc.Pfizer, Inc.Sanofi Genzyme
Appropriate use of Biomarker and Genetic Testing in the Diagnosis and Management of Patients with Prostate Cancer
Host: Jay D. Raman, MD, FACS Co-Hosts: Veda Giri, MD and Todd Morgan, MD
CME Available: auau.auanet.org/node/37333
At the conclusion of this activity, participants will be able to 1. Assess how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically meaningful prostate cancer while avoiding unnecessary biopsies and detection of clinically unimportant cancers. 2. Discuss the available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use and the clinical scenarios in which they are most valuable to be used. 3. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy and immunotherapy.
ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme
Novel Imaging for Genitourinary Cancers
Host: Jay D. Raman, MD, FACS Co-Host: Marc Bjurlin, DO
CME Available: https://auau.auanet.org/node/37333
At the conclusion of this activity, participants will be able to 1. Review clinical trials and available PET imaging agents for the detection of prostate, kidney and urothelial cancer. 2. Assess the indications, risks, and benefits of incorporating PET imaging to guide treatment of urologic cancer.
ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme
Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer
Host: Jay D. Raman, MD, FACS Co-Host: Alicia Morgans, MD, MPH and Kelly Stratton, MD
CME Available: auau.auanet.org/node/37317
At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Prioritize or stratify treatment options for metastatic prostate cancer. 3. Describe the mechanism of action and role of immune checkpoint inhibitors for advanced prostate cancer. 4. Identify management of side effects and adverse events that patients experience for systemic therapies for advanced prostate cancer.
ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme
Today’s episode is a special preview from the 2022 Update Series. The Update Series, the AUA’s most popular self-study CME product is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. Available in three convenient formats – online, print and audio – the Update Series delivers you 40 concise, practical lessons on timely topics including state-of-the-art surgical techniques.
For more episodes like this one or to subscribe to the 2023 Update Series Volume 42, visit the AUAUniversity at auanet.org/update.
Application of the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline in Clinical Practice
Host: Jay D. Raman, MD, FACS Co-Host: Michael S. Cookson, MD, MMHC
CME Available: https://auau.auanet.org/node/37309
At the conclusion of this activity, participants will be able to: 1. Interpret the evidence and outcomes on the treatment of M0 HSPC, M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced Prostate Cancer Guideline encompassing metastatic HSPC and CRPC disease. 2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.
ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme
Negotiating Skills 101 – Key Steps to Becoming a Good Negotiator
Host: Jennifer Miles-Thomas, MD, FPMRS Co-Host: Angelo Baccala, MD, FACS, MBA
Welcome to the AUAUniversity Podcast. Today we are announcing the debut of the New AUA Leadership & Business Podcast where urologic professionals can experience the practical application of business acumen essential to successful navigating today’s rapidly changing business environment. We are happy to share with you this AUA Leadership & Business inaugural episode, Negotiating Skills 101 – Key Steps to Becoming a Good Negotiator, where Dr. Angelo Baccala joins host Dr. Jennifer Miles-Thomas to discuss the key points to good negotiating skills that can be used in the workplace as well as personally in day-to-day life.
Make AUA Leadership & Business your go-to podcast! Subscribe today by searching “AUA Leadership & Business” on your favorite podcast app.
Primary Palliative Care in Urology
Host: Jay D. Raman, MD, FACS Co-Hosts: John L. Gore, MD, MSHS; Jonathan Bergman, MD, MPH
Outline: Segment #1: What is palliative care? Segment #2: What evidence is there for the benefit of palliative care? Segment #3: Who supports early palliative care for patients with advanced disease? Segment #4: Why hasn’t access to palliative care been achieved for individuals with advanced disease? Segment #5: What is the current state of palliative care utilization in urology, and is there a better model that could succeed in urology?
AUA Urology Core Curriculum: https://auau.auanet.org/core
Host: Jay D. Raman, MD, FACS Co-Host: Priyanka Gupta, MD
Outline: 1. Diagnosis and evaluation 2. Non-surgical treatments 3. Urethral bulking agents 4. Open repairs 5. Synthetic slings
Cultural Barriers for Ethnic Minorities
CME Available: auau.auanet.org/node/35727
Moderator: Jay D. Raman, MD, FACS Co-Hosts: Adam Murphy, MD, MBA, MSCI
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify two specific forms of medical mistrust that can be addressed by clinicians (e.g. belief in doctors as drug pushers incentivized by pharmaceutical companies and belief that placebos are often given to minority patients on clinical trials). 2. Identify common modifiable barriers that impact ethnic minorities (e.g. social support through support groups or patient advocates or home care services or insurance enrollment through critical treatment periods or language).
ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: Astellas AstraZeneca Bayer Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc. Pfizer, Inc.
AUA Urology Core Curriculum: auau.auanet.org/core
Host: Jay D. Raman, MD, FACS Co-Host: Adrien Bernstein, MD
Outline: 1. The aging population and their unique needs 2. Geriatric Assessment 3. Practical applications of geriatric centered surgical care 4. Palliative care as part of Geriatric oncology
Host: Jay D. Raman, MD, FACS Guest: A. Lenore Ackerman, MD, PhD
For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University
AUA Urology Core Curriculum: https://auau.auanet.org/core
Host: Jay D. Raman, MD, FACS Co-Host: Zachary Klaassen, MD, MSC
Outline: 1. Understand the importance of Cancer Survivorship Plans 2. Mental Health Among GU Cancer Survivors 3. Importance of understanding financial toxicity 4. Prostate Cancer 5. Bladder Cancer 6. Kidney cancer 7. Testicular Cancer
Advancing Equitable Opportunities for Recruitment of Diverse Patients to Clinical Trials (Race, Ethnicity, Women, Older Patients)
CME Available: https://auau.auanet.org/node/35728
Moderator: Jay D. Raman, MD, FACS Co-Hosts: Adam Murphy, MD, MBA, MSCI; Sarah Psutka, MD, MS
ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: Astellas AstraZeneca Bayer Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc. Pfizer, Inc.
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Develop recruitment strategies for equitable recruitment of diverse patients to clinic trials to expand access to clinical trial enrollment for patients who are traditionally underrepresented in clinical trials. 2. Discuss pragmatic trial designs that may subvert some of these traditional barriers to enrolling patients to clinical trials.
AUA Urology Core Curriculum: https://auau.auanet.org/core
Host: Jay D. Raman, MD, FACS Co-Host: Marcelino E. Rivera, MD
Outline: 1. Acute stone event and Radiographic evaluation 2. Shock Wave Lithotripsy 3. Ureteroscopy 4. Percutaneous Nephrolithotomy 5. Intracorporeal Lithotripsy 6. Special considerations
AUA Urology Core Curriculum: https://auau.auanet.org/core
Host: Jay D. Raman, MD, FACS Co-Host: Maurice M. Garcia, MD, MAS
Outline: Segment #1 Topic: How did you get into the field of transgender surgery? Segment #2 Topic: Tell us about the patients who come to you for surgery. Who are they? Segment #3 Topic Overview of feminizing genital GAS. Segment #4 Topic: Overview of masculinizing genital GAS Segment #5 Topic: Challenges and “new frontiers” in transgender surgery
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer (2022)
CME Available: https://auau.auanet.org/node/36089
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Differentiate among the subtypes of kidney cancer, with emphasis on clinical management decisions, and outline ways in which knowledge of kidney cancer subtypes can alter surgical approach. 2. Apply advanced strategies for partial nephrectomy for patients with endophytic, hilar and multiple tumors including role of warm ischemia, intraoperative ultrasound, techniques for hemostatic control, the role of off-clamp and selective hilar clamping, the use of the retroperitoneal approach and methods for renorrhaphy. 3. Employ techniques for management of large and/or locally advanced tumors including management of renal vein or inferior vena cava invasion and the use of lymphadenectomy. 4. Identify the role of cytoreductive nephrectomy and/or resection of metastatic foci in patients with advanced disease. 5. Identify new and emerging targeted therapy and immuno-oncology options for patients with locally advanced and advanced kidney cancer and the role of adjuvant therapy.
Operationalizing Checkpoint Inhibitors in Urologic Practice (2022)
CME Available: https://auau.auanet.org/node/36084
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Discuss how to develop a structured approach for administering checkpoint inhibitors in urologic practice as part of a structured program. 2. Manage adverse events from checkpoint inhibitors 3. Identify practice implications of implementing a checkpoint inhibitor program
Financial Toxicity as Drugs Move Earlier into Treatment Paradigm and How This Relates to Disparities in Treatment Patterns
CME Available: https://auau.auanet.org/node/35729
Moderator: Jay D. Raman, MD, FACS Co-Hosts: Sarah Psutka, MD, MS
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Define the magnitude of financial toxicity/economic implications across GU malignancies currently. 2. Forecast the potential changes/increases in financial burden associated with moving systemic therapies earlier in treatment paradigms for patients with GU malignancies.
ACKNOWLEDGEMENTS Support provided by independent educational grants from: Astellas AstraZeneca Bayer Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc. Pfizer, Inc.
Incorporating Genomic Testing for Prostate Cancer into Your Practice (2022)
CME Available: https://auau.auanet.org/node/36074
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Discuss the research studies that led to the approval of genomic testing for prostate cancer 2. Order appropriate genomic testing based on a patient's unique clinical situation 3. State the NCCN and AUA guidelines for genomic testing for prostate cancer 4. Discern the different prognostic clinical endpoints provided by various genomic tests 5. Recognize candidates for, and implications of, germline testing for prostate cancer
Refractory Overactive Bladder: How to Select 3rd-Line Therapies and Optimize Outcomes (2022)
CME Available: https://auau.auanet.org/node/36033
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Describe the various 3rd line therapies available to treat refractory overactive bladder (OAB) and be able to discuss the pros and cons of each of the 3rd line therapies available to treat refractory OAB. 2. Explain with the current data regarding outcomes of percutaneous tibial nerve stimulation (PTNS), onabotulinumtoxinA and sacral neuromodulation for treatment of refractory OAB. 3. Outline how to perform PTNS. 4. Report how to perform onabotunlinumtoxinA injections in the office or outpatient setting.. 5. Review techniques in optimal lead placement for sacral neuromodulation, programming and troubleshooting.
Bladder Cancer Treatment Dilemmas: The Cases You Face and What To Do about Them (2022)
CME Available: https://auau.auanet.org/node/36049
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Assign risk stratification to patients with bladder cancer. 2. Adapt treatment choices depending on risk of disease and availability of bacillus Calmette-Guérin (BCG). 3. Individualize patient surveillance needs. 4. Provide broadened treatment options beyond intravesical therapy.
Genetic Testing in Prostate Cancer: Clinical Implications for Early Detection and Management of Localized and Advanced Disease Webcast (2022)
CME Available: https://auau.auanet.org/node/36044
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening. 2. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 3. Interpret results of genetic testing and relay this information to patients in order to facilitate shared decision making based on the test results. 4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.
CME Available: https://auau.auanet.org/node/35725
Moderator: Jay D. Raman, MD, FACS Co-Hosts: Channa Amarasekera, MD; Simon Rosser, PhD, MPH
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify two specific surgical side effects that may be of interest to a patient who undergoes a prostatectomy (e.g. ED treatment efficacy for anal penetration, climacturia, anejaculation). 2. Ask relevant questions about sexual practices that may impact the side effects that are of interest to them (partner with men, women and both and anal receptive vs. anal penetration sex).
ACKNOWLEDGEMENTS Support provided by independent educational grants from: Astellas AstraZeneca Bayer Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck & Co., Inc. Pfizer, Inc.
Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment(2022)
CME Available: https://auau.auanet.org/node/36065
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma. 2. Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma. 3. Identify appropriate treatment options for management of complex cases.
Contemporary Pharmacotherapy for OAB 2022: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2022)
CME Available: https://auau.auanet.org/node/36028
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy. 3. Explain the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB.
Controversies, Confusion, and the Future of Urologic Post-Operative Opioid Prescribing Reduction Strategies
CME Available: https://auau.auanet.org/node/35160
Course Director: Jennifer Robles, MD, MPH Faculty: Chad Brummett, MD; Gregory Auffenberg, MD, MS; Hitya Abraham, MD; Kevan Sternberg, MD
After participating in this activity, learners will be able to: 1. Identify at least one non-pharmaceutical method they can practically implement to manage post-operative pain and reduce post-operative opioid prescribing. 2. Discuss multi-modal pain control and identify at least two non-opioid medications which can be used to manage post-operative pain and reduce post-operative opioid prescribing.
Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach (2022)
CME Available: https://auau.auanet.org/node/36020
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Identify low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC) 2. Recommend treatment for NMIBC based on risk stratification. 3. Identify bacillus Calmette-Guérin (BCG) unresponsive NMIBC and novel immune-based strategies and intravesical therapies. 4. Manage invasive bladder cancer including surgery, neoadjuvant and adjuvant chemotherapy and bladder preservation strategies in patients with muscle invasive bladder cancer. This will include chemotherapy indications and the role of immunotherapy in the management. 5. Manage upper tract tumors, both low grade and high grade, including renal preservation when appropriate, neoadjuvant therapy when indicated and surgical management strategies.
The Changing Face of Advanced Prostate Cancer 2022(2022)
CME Available: https://auau.auanet.org/node/36010
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be able to offer additional therapies that extend survival. 2. Recognize high volume new M1 prostate cancer to be able to refer to a genitourinary (GU) medical oncologist for systemic chemotherapy. 3. Diagnose M0 metastatic CRPC and educate patients about using novel oral AR targeted therapeutics added to traditional ADT as a way to improve their patient's overall and radiographic progression-free survival. 4. Identify the differences between these AR targeted oral agents and to educate patients about side effects and toxicities. 5. Describe the latest phase III randomized control trial (RCT) results for new therapies in M1 CRPC.
Host: Jay D. Raman, MD, FACS Guest: Akanksha Mehta, MD, MS
For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University
Diversity Equity and Inclusion in Urology: What Do We Need to Know?
CME Available: https://auau.auanet.org/node/35746
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify the different forms of racism and, more importantly, identify their own subconscious personal bias. 2. Identify the impact of race on medical education, research and clinical care. 3. Identify how DEI initiatives can positively impact the practice of urology. 4. Examine innovative methodologies employed to increase the numbers of underrepresented groups in urology. 5. Participate in activities to encourage and support individualism among urology team members.
Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities
CME Available: https://auau.auanet.org/node/36003
LEARNING OBJECTIVES At the conclusion of this course, participants will be able to: 1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney and urothelial cancer detection, staging and follow-up. 2. Determine the benefits of combined functional and anatomical information gained through accurate matching of anatomical (CT/MRI) and functional (PET) images. 3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests. 4. Utilize performance characteristics of standard and emerging molecular imaging modalities to stage urologic oncology patients. 5. Describe the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.
CME Available: https://auau.auanet.org/node/35793
Course Director: Amy Krambeck, MD Faculty: Dean Elterman, MD; Steven Kaplan, MD; Lori Lerner, MD
ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Cook Medical Olympus Corporation of the Americas
LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Identify the role of diagnostic testing in making the accurate diagnosis of mLUTS using the new benign BPH guidelines. 2. Recognize the various agents available to treat mLUTS. 3. Describe the indications for the various ablative BPH procedures. 4. Illustrate the impact of current therapeutic strategies on both voiding and sexual dysfunction. 5. Identify the role of the AUA guidelines for BPH for the surgical and medical management of BPH.
CME Available: https://auau.auanet.org/node/35710
Course Director: Stephen A. Boorjian, MD Faculty: Leonard G. Gomella, MD, FACS; David F. Jarrard, MD; Alicia K. Morgans, MD, MPH
ACKNOWLEDGMENTS: This educational activity is supported by independent education grants from: Astellas AstraZeneca Merck & Co., Inc. Pfizer, Inc.
At the conclusion of the activity, participants will be able to:
LEARNING OBJECTIVES: 1. Describe recent developments in the medical management of advanced prostate cancer. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 2. Discuss clinical investigations in the treatment of advanced prostate cancer. 3. Analyze the risks and benefits of treatment for advanced prostate cancer. 4. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.
CME Available: https://auau.auanet.org/node/35599
Course Director: David A. Ginsberg, MD Faculty: Anne P. Cameron, MD, FRCSC, FPMRS; Sara M. Lenherr, MD, MS, FPRMS, Eric Rovner, MD; Eric Rovner, MD
ACKNOWLEDGEMENTS This educational activity is supported by an independent educational grant from: Urovant
LEARNING OBJECTIVES At the conclusion of the activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies. 2. Describe the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 3. Discuss optimal use of third line therapies in order to maximize clinical benefit. 4. Counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB.
Publishing Ethics
Co-Host: John P. Mulhall, MD
Outline: Segment 1: The 4 R's of scientific publishing Segment 2: Plagiarism Segment 3: Authorship issues Segment 4: Conflict of interest Segment 5: IRB (IACUC) issues Segment 6: Fabrication/Falsification Segment 7: Reviewer malpractice Segment 8: Predatory journals
Host: Jay D. Raman, MD, FACS Guest: John P. Mulhall, MD
Outline: Segment 1: The 4 R's of Scientific Publishing Segment 2: Plagiarism Segment 3: Authorship Issues Segment 4: Conflict of Interest Segment 5: IRB (IACUC)Issues Segment 6: Fabrication/Falsification Segment 7: Reviewer Malpractice Segment 8: Predatory Journals
For more information, please visit: AUAnet.org/University
Adolescent and Young Adult (AYA) Oncology Focusing on Translocation RCC
Co-Host: Nick G. Cost, MD
Outline: Topic 1: Adolescents with cancer are different from both children and older adults with cancer Topic 2: Differences in biology Topic 3: Differences in clinical behavior Topic 4: Specific clinical trial options Topic 5: Summary – “Now what? What should I do the next time I see an AYA with kidney cancer?”
CME Available: https://auau.auanet.org/node/35405
Moderator: Todd Morgan, MD Panelists: Maria Carlo, MD; Elisabeth Heath, MD, FACP; Brian Helfand, MD
At the conclusion of this activity, participants will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients, explain how to counsel patients about genetic testing, and how to order and interpret these tests. 2. Explain how mutations in DNA damage repair genes can lead to the development of aggressive prostate cancer and the implications for treatment decisions. 3. Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition for cancer treatment. 4. Discuss clinical trial data assessing the efficacy of PARP inhibitors in advanced prostate cancer, including patient populations and clinical outcomes for each trial.
ACKNOWLEDGEMENTS Support provided by independent educational grants from: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck
New Minimally Invasive BPH Treatment Options
Co-Host: John V. Kaspar, MD
Acknowledgements: This podcast was funded by and developed in collaboration with Olympus Corporation.
Outline: Segment 1: BPH patient needs Segment 2: AUA Guideline changes Segment 3: MIST procedures and patient selection Segment 4: Site of service for MIST treatment Segment 5: Anatomical considerations between therapies
CME Available: https://auau.auanet.org/node/35401
Learning Objectives: After participating in this educational series, participants will be able to: 1. List advanced prostate cancer disease states (mHSPC); M0 CRPC and M1 CRPC) and be able to identify these patients in urologic practice. 2. Identify available approved therapies and outcomes for each of these disease states: MHSPC, M0 CRPC, M1 CRPC. 3. Demonstrate the appropriate indications, unique mechanisms of action and side effects of new and existing androgen axis agents, immunotherapies, chemotherapeutic agents and bone targeted therapies. 4. Explain the sequencing of available therapies, as well as identifying adverse events that might occur when considering combination therapy. 5. Review the evidence and outcomes on androgen deprivation treatment alone and in combination as outlined in the newly released Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline.
Acknowledgements: Support provided by independent educational grants from: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck
Host: Jay D. Raman, MD, FACS Guest: David B. Bock, MD, FACS
Outline: Segment 1: Need for Office Sedation Segment 2: Types of procedures for which sedation can be utilized in the office Segment 3: Types of Anesthesia Segment 4: Office Readiness Segment 5: Implementation
For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University
Host: Jay D. Raman, MD, FACS Guest: Badar M. Mian, MD, FACS
Outline: Segment 1: What are the main issues with transrectal biopsy? Segment 2: Proposed advantages of transperineal biopsy Segment 3: Some of the difference between the two techniques Segment 4: Ongoing RCTs Segment 5: Lessons learned during our RCT
For more information, please visit: AUAnet.org/University
Moderator: Samir S. Taneja, MD
Panelists: Simpa Salami, MBBS, MPH Edouard Trabulsi, MD Brian Shuch, MD Cheryl T. Lee, MD
Moderator: Prokar Dasgupta, MD 3D Printing : Jamie Landman, MD Assessment of Surgical Competence: Andrew Hung, MD
Moderator: Nelson Bennett, MD Panel: Hypogonadism: Mohit Khera, MD Erectile Dysfunction: Alan Shindel, MD Telemedicine: Faysal Yafi, MD Infertility: Ranjith Ramasamy, MD
Title: AUA2021 John K. Lattimer Lecture - Kidney Stones: Is Prevention Possible? Speaker: Glenn M. Preminger, MD Release: January 12
How to Safely and Properly Administer Immunotherapies Podcast (2021)
CME Available: https://auau.auanet.org/node/33496
ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Management of Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies Podcast (2021)
CME Available: auau.auanet.org/node/33488
ACKNOWLEDGEMENTS This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Peer-Reviewed Guidance on How to Manage Immune-Related Adverse Events & Toxicities Podcast (2021)
CME Available: auau.auanet.org/node/33492
This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Update Podcast (2021)
CME Available: auau.auanet.org/node/33467
This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.
CME Available: auau.auanet.org/node/31823
At the conclusion of this educational series, participants will be able to: 1. Discuss the impact of SDM on patients and on patient-clinician communication. 2. Identify at least one implementation strategy for using SDM in clinical practice. 3. Apply SDM techniques in a role-playing exercise with other colleagues. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases. 4. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.
Novel Imaging for High Risk Prostate Cancer Podcast (2021)
CME Available: auau.auanet.org/node/33480
This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Evolving Landscape of Androgen Deprivation Therapy in Advanced Prostate Cancer Podcast (2021)
CME Available: auau.auanet.org/node/33472
This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Identification and Management of Comorbid Conditions in the Patient with Advanced Prostate Cancer Podcast (2021)
CME Available: https://auau.auanet.org/node/33476
This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
Role of Genetic Testing in Advanced M1 CRPC & M1 CPRC Post-docetaxel, Neuroendocrine Cancer and End of Life Care Presented by Leonard Gomella, MD and Joshua Lang, MD
https://auau.auanet.org/node/34071
Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme
Optimizing the Treatment of Complicated UTIs
CME Available: https://auau.auanet.org/node/33500
ACKNOWLEDGEMENT: This activity is supported by an independent educational grant from Spero Therapeutics.
Early M1 CRPC & Advanced M1 CRPC Presented by Kelly Stratton, MD and Deborah Kaye, MD
CME Available: https://auau.auanet.org/node/34065
Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme
Advances in Immuno-Oncology in Urothelial Carcinoma Podcast (2021)
CME Available: https://auau.auanet.org/node/33484
This educational series is supported by independent educational grants from: Astellas AstraZeneca Lantheus Medical Imaging Merck Pfizer, Inc.
BCR and Novel Pet Imaging & M0 CRPC Presented by Stephen Boorjian, MD and Michael Cookson, MD
CME Available: https://auau.auanet.org/node/34059
Acknowledgements Support provided by independent educational grants from: Amgen Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Exact Sciences Corporation Merck Pfizer, Inc. Sanofi Genzyme
CME Available: https://auau.auanet.org/node/33094
Acknowledgements This educational activity is supported by an independent educational grant from: Urovant
CME Available: https://auau.auanet.org/node/33093
At the conclusion of the activity, participants will be able to: 1. Describe recent developments in the medical management of advanced prostate cancer. 2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 3. Discuss clinical investigations in the treatment of advanced prostate cancer. 4. Analyze the risks and benefits of treatment for advanced prostate cancer. 5. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.
Acknowledgements This educational activity is supported by independent educational grants from Astellas, AstraZeneca, Merck, Pfizer, Inc.
Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.
CME Available: auau.auanet.org/node/31819
At the conclusion of this educational series, participants will be able to: 1. Discuss the impact of SDM on patients and on patient-clinician communication. 2. Identify at least one implementation strategy for using SDM in clinical practice. 3. Apply SDM techniques in a role-playing exercise with other colleagues. 4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases. 5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.
Optimizing Pre-Operative Care for Patients Undergoing Urologic Surgery by AUAUniversity
This podcast was funded by and developed in collaboration with AstraZeneca.
Learning Objectives: At the conclusion of this activity, participants will be able to: 1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy. 2. Evaluate available clinical safety and efficacy data for PARP Inhibitors. 3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer. 4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.
For more information: https://auau.auanet.org/content/overview-parpi-adverse-event-management-podcast-2021
This podcast was funded by and developed in collaboration with AstraZeneca.
Learning Objectives: At the conclusion of this activity, participants will be able to: 1. Identify the role of genomic testing in men with different stages of prostate cancer. 2. Recognize the need for collaboration with genetic counselors for optimal genetic evaluation tailored to an individual prostate cancer patient. 3. Explain the criteria for genomic testing of prostate cancer patients across the disease spectrum, current NCCN testing guidelines, difference between germline and somatic testing, different testing modalities currently available gene panels, options for testing these men, and appropriate timing for testing. 4. Interpret the results of genomic testing, implications for shared‐decision with patients based on the test results, and impact on novel therapies and personalized treatment for prostate cancer care. 5. Apply best practices and lessons learned for operationalizing testing and testing workflows in urology practices.
For more information: https://auau.auanet.org/content/genomic-testing-prostate-cancer-podcast-podcast-2021
Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.
CME Available: https://auau.auanet.org/node/31815
At the conclusion of this educational series, participants will be able to: 1. Discuss the impact of SDM on patients and on patient-clinician communication. 2. Identify at least one implementation strategy for using SDM in clinical practice. 3. Apply SDM techniques in a role-playing exercise with other colleagues. 4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases. 5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.
This educational series is supported by independent educational grants from Olympus Corporation of the Americas and Teleflex.
CME Available: https://auau.auanet.org/node/32295
At the conclusion of this activity, participants will be able to: 1. Describe the role of the AUA Clinical Guidelines for the Surgical Management BPH. 2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them. 3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.
Designed to encourage high quality, evidence-based testing and care of patients with bladder cancer, this podcast episode focuses on Genetic Testing for Bladder Cancer. Listen today to discover the differences between molecular markers and genetic testing, how genetic testing for bladder cancer is performed and current considerations of genetic findings.
Co-Host: Neal Shore, MD, FACS
Acknowledgement: This podcast was funded by Janssen Oncology.
For more information: https://auau.auanet.org/content/genetic-testing-bladder-cancer-podcast-2021
Contemporary Pharmacotherapy for OAB 2021: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2021)
CME Available: https://auau.auanet.org/node/31460
ACKNOWLEDGEMENTS Support provided by independent educational grants from AbbVie, Astellas, Medtronic, Urovant Sciences, Inc.
At the conclusion of the activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB). 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the anti-muscarinics and beta-3 agonists and combination therapy. 3. Express the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB.
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider (2021)
CME Available: https://auau.auanet.org/node/31450
ACKNOWLEDGEMENTS Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.
At the conclusion of the activity, participants will be able to: 1. Explain the mechanism of checkpoint inhibitors. 2. Describe historical and novel treatments for systemic prostate cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map. 3. Describe historical and novel treatments for systemic bladder cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map. 4. Describe historical and novel treatments for systemic kidney cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
Trimodality Therapy for Management of Muscle Invasive Bladder Cancer (2021)
CME Available: https://auau.auanet.org/node/31470
ACKNOWLEDGEMENTS Support provided by independent educational grants from AstraZeneca, Bristol Myers Squibb and Merck.
At the conclusion of the activity, participants will be able to: 1. Demonstrate an understanding of prospective randomized trials and large institutional experiences in tri-modality therapy for muscularis propria invasive bladder cancer. 2. Identify which patients are candidates for tri-modal bladder sparing therapy, and which patients are not candidates and should instead undergo radical cystectomy. 3. Explain the technique and importance of aggressive initial transurethral resection, repeat transurethral resection and ongoing cystoscopic surveillance of the bladder. 4. Outline the coordinated multidisciplinary technique in tri-modality therapy, including radio-sensitizing chemotherapy agents, radiation fields, and adjuvant chemotherapy. 5. Describe the indications for salvage cystectomy, discuss management of noninvasive recurrences, and understand the quality of life and potential toxicities after tri-modal therapy.
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer (2021)
CME Available: https://auau.auanet.org/node/31465
ACKNOWLEDGEMENTS Support provided by independent educational grants from AstraZeneca, Bristol Myers Squibb and Merck.
At the conclusion of the activity, participants will be able to: 1. Differentiate among the subtypes of kidney cancer, with emphasis on clinical management decisions and outline ways in which knowledge of kidney cancer subtypes can alter surgical approach. 2. Apply advanced strategies for partial nephrectomy for patients with endophytic, hilar and multiple tumors including role of warm ischemia, intraoperative ultrasound, techniques for hemostatic control, the role of off-clamp and selective hilar clamping, the use of the retroperitoneal approach, and methods for renorrhaphy. 3. Employ techniques for management of large and/or locally advanced tumors including management of renal vein or inferior vena cava invasion and the use of lymphadenectomy. 4. Identify the role of cytoreductive nephrectomy and/or resection of metastatic foci in patients with advanced disease. 5. Describe new and emerging targeted therapy and immuno-oncology options for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy.
Incorporating Genomic Testing For Prostate Cancer into Your Practice (2021)
CME Available: https://auau.auanet.org/node/31455
ACKNOWLEDGEMENTS Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.
At the conclusion of the activity, participants will be able to: 1. Describe the seminal validation studies for prostate cancer genomic testing. 2. List the different prognostic endpoints provided by various genomic tests. 3. Identify appropriate genomic testing based on a patient's unique clinical characteristics. 4. Review the AUA and NCCN guidelines for genomic testing for prostate cancer.
This podcast webinar will introduce attendees to current diversity initiatives within urology. Panelists representing these programs will discuss the benefits of promoting diversity in urology, how their initiatives began, available resources and what urology residency programs and medical schools can do to promote diversity.
How to Manage a 65 Year Old Man with Bothersome LUTS and Underactive Bladder by AUAUniversity
This educational series is supported by independent educational grants from AstraZeneca and Merck.
CME Available: https://auau.auanet.org/node/31224
Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.
Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.
Upon completion of this activity, participants will be able to: 1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice. 2. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer. 3. Discuss the impact of shared-decision making on patient and on patient-clinician communication. 4. Describe how telemedicine can be successfully incorporated into the care continuum of patients with advanced prostate cancer.
Multidisciplinary Discussion On Fertility, Hypogonadism & Sexual Function For Testis Cancer Patients by AUAUniversity
This educational series is supported by independent educational grants from AstraZeneca and Merck.
CME Available: https://auau.auanet.org/node/31223
Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.
Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.
Upon completion of this activity, participants will be able to: 1. Describe the role of the enzyme poly ADP ribose polymerase (PARP) in carcinogenesis as well as the mechanism of PARP inhibition. 2. Discuss the current clinical trials associated with PARP inhibitors. 3. Describe the patient populations associated with each trial. 4. State the clinical outcomes for each trial.
This educational series is supported by independent educational grants from AstraZeneca and Merck.
CME Available: https://auau.auanet.org/node/31198
Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.
Upon completion of this activity, participants will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients and the options for testing these men. 2. Explain importance of testing for germline pathogenic variants and their implication for utilizing novel targeted therapies such as PARP inhibitors and for cascade testing among patient family members. 3. Identify men with BRCA1/2 pathogenic variants and variants in other key inherited syndromes, regarding their prostate cancer and other cancer risk, and implement strategies for cancer screening and management.
This educational series is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Pfizer, Inc.
CME Available: https://auau.auanet.org/node/30861
In 2020, the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline was released and will provide critical guidance as the management of advanced prostate cancer patients continues to expand. To increase urologists understanding of how to translate the latest scientific advances and the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline into their clinical practice, the featured 60-minute panel discussion includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of mHSPC. Faculty will highlight the management of patients with advanced prostate cancer and how therapeutic options have been incorporated into evidence-based guidelines.
Learning Objectives: At the conclusion of the activity, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of metastatic hormone sensitive prostate cancer (mHSPC). 2. Review the evidence and outcomes on the treatment of mHSPC as outlined in the newly released Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline. 3. Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice. 4. Analyze breakthrough treatments in the management of advanced and mHSPC. 5. Describe the indications and combinations for treatment with approved agents in the management of mHSPC.
At the conclusion of this activity, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of advanced bladder cancer and analyze the risks and benefits of the new and emerging treatment options. 2.Describe the mechanism of action and associated side effects of the new adjuvant therapy. 3. Differentiate the roles between the urologist and medical oncologist in the care of patients with bladder cancer. 4. Discuss the opportunities for the coordination of care between the urologists and medical oncologists.
This educational series is supported by an independent educational grant from: Bristol Myers Squibb
CME available: https://auau.auanet.org/node/30870
Bulbar Urethral Strictures 101 - A Review Of The Guidelines And Basic Management Options by AUAUniversity
Learning Objective: At the conclusion of this continuing medical education activity, the participant will be able to select different strategies for ureteroscopic renal stone surgery, determine how laser parameter selection can improve lithotripsy efficiency and identify the important safety considerations to optimize patient outcomes.
At the conclusion of this activity, participants will be able to: 1. Explain the sequencing of novel therapies and be able to identify patient progression of disease. 2. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.
This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
CME Available: auau.auanet.org/node/29811
At the conclusion of this activity, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Explain best practices in MIBC and NMIBC patient selection for various treatment options. 3. Facilitate discussions with patients and caregivers regarding their treatment options.
This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc.
CME Available: auau.auanet.org/node/29836
Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020)
Presented by Leonard Gomella, MD and Joshua Lang, MD
This educational activity is supported by independent educational grants from:
AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc.
CME Available: https://auau.auanet.org/node/30124
Presented by Kelly Stratton, MD and Alicia Morgans, MD
This educational activity is supported by independent educational grants from:
AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc.
CME Available: https://auau.auanet.org/node/30123
Case-Based Discussion: BCR and mHSPC and M0 CRPC
Presented by Stephen Boorjian, MD and Michael Cookson, MD
This educational activity is supported by independent educational grants from:
AbbVie Astellas AstraZeneca Bayer HealthCare Pharmaceuticals Inc. Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc.
CME Available: https://auau.auanet.org/node/30122
At the conclusion of this activity, participants will be able to: 1. Identify the role of genetic testing in men with advanced, metastatic and CRPC. 2. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 3. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results. 4. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.
This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
At the conclusion of this activity, participants will be able to: 1. Examine racial and geographic disparities in in prostate cancer and prostate cancer care. 2. Identify important causes for disparities as well as possible remedies to address these causes.
This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
At the conclusion of this activity, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.
This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
CME Available: https://auau.auanet.org/node/29841
At the conclusion of this activity, participants will be able to: 1. Review the evidence and outcomes on the treatment of M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced, Metastatic and CRPC guidelines. 2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice
This educational series is supported by independent educational grants from: • Astellas • AstraZeneca • Bristol Myers Squibb • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC • Merck • Pfizer, Inc • Sanofi Genzyme • UroGen Pharma, Inc.
CME Available: https://auau.auanet.org/node/30174
At the conclusion of this activity, participants will be able to: 1. Describe new and emerging targeted for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy. 2. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC. 3. Facilitate discussions with patients and caregivers regarding RCC treatment options.
This educational series is supported by independent educational grants from:
Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
CME Available: https://auau.auanet.org/node/29851
Immune Checkpoint Inhibitors in RCC At the conclusion of this activity, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage immune related adverse events.
This educational series is supported by independent educational grants from:
Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
CME Available: https://auau.auanet.org/node/29846
The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC At the conclusion of this activity, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents.
This educational series is supported by independent educational grants from:
Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
CME Available: https://auau.auanet.org/node/29831
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 At the conclusion of this activity, participants will be able to: 1. Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC). 2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 3. Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC.
This educational series is supported by independent educational grants from:
Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc.
CME Available: https://auau.auanet.org/node/29816
Course Description: The course is centered on reviewing medical management and prevention of kidney stones. A focus is on the AUA guidelines for the medical management of stones. The course is focused on practical information, for example, how to interpret 24 hour urines, when to prescribe medication. It also has a focus on dietary management for stones.
Learning Objectives: Upon completion of this activity, participants will be able to: 1. Interpret a 24 hour urine collection and identify underlying metabolic causes for recurrent stone disease. 2. Prescribe appropriate medical treatment for the prevention of kidney stones based on findings on a 24 hour urine collection. 3. Prescribe targeted dietary changes for underlying metabolic abnormalities on 24 hour urine testing such as hypercalciuria, hyperoxaluria, and hypocitraturia.
Course Description: The diagnosis and management of Male Lower Urinary Tract Symptoms (mLUTS) and benign prostatic hyperplasia (BPH) has evolved dramatically over the past 5 years with changing algorithms. The AUA BPH Guidelines were revised in 2018 focusing primarily on diagnostic algorithms and surgical modalities. The 2020 Guidelines will incorporate recommendations about medical therapies. This course is designed to review, discuss and develop a coherent diagnostic and treatment strategy for men with mLUTS. This will include risk factors such as obesity, the role of both AUA and international guidelines, established algorithms, medical therapy with both mono and combination therapy with agents such as alpha blockers, antimuscarinics, beta - 3 agonists, 5-alpha reductase inhibitors, PDE - 5 inhibitors and surgical options including minimally invasive (UroLift / Rezum) and surgical options (electrosurgical, laser, aquablation). In addition, how these agents dovetail with sexual function and testosterone replacement therapy will be highlighted. Finally, pharmaco economics and the impact of long term therapy as well as surgical outcomes will be debated.
Learning Objectives: Upon completion of this activity, participants will be able to: 1. Recognize the various medical agents available to treat mLUTS and their appropriate use. 2. Identify common aspects of metabolic dysfunction and its relationship to voiding and sexual health. 3. Utilize, understand and employ the AUA Guidelines for BPH. 4. Employ the proper diagnostic algorithms to manage men with LUTS with medical, minimally invasive and surgical therapies.
This educational series is supported by an independent educational grant from: AstraZeneca; Merck; Pfizer Inc.
CME Available: https://auau.auanet.org/node/29200
Course Description: Over the last several years, there has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer. Urologists are suddenly being confronted with new information surrounding screening guidelines for men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations. To increase urologists understanding related to the newest treatment options for prostate cancer, the featured 60-minute panel discussion led by experts in their field, will explore how to translate the latest scientific advances into routine clinical practice, improving the care of patients who are at a markedly-elevated risk of progressions and death from prostate cancer. The Genetic Testing in Prostate Cancer: Considerations for Urologists and their Patients Webinar will be recorded and available in webcast format on AUAUniversity and AUA’s YouTube channel. Additionally, the content will be released as an episode on AUA’s podcast. Learners will also be provided with links to access a patient and caregiver video and fact sheet produced by the Urology Care Foundation to increase patient understanding of genetic testing as it relates to prostate cancer, and facilitate enhanced patient – physician communications in regards to treatment options. Learning Objectives: At the conclusion of the activity, participants will be able to: 1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 2. Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results. 3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors. 4. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.
Join Drs. Brian Matlaga and Ryan Hsi as they share insights into diagnostics, therapeutic options, and treatment outcomes for urinary stone disease.
Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guest: Ryan Hsi, MD, Vanderbilt University
This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.
Course Description: This course tackles key controversies in surgical stone disease and elucidates the most current rationale to varying treatments using a case-based scenarios. Two well-known senior experts give honest and clear assessments of the field in these controversial areas. Active discussion is encouraged, and the discussion favors more experienced endourologists. Controversies include: dusting vs basketing, mini PCNL vs. standard PCNL, supine vs prone PCNL, micro PCNL vs ureteroscopy, wireless vs safety wire ureteroscopy, stents vs no stents, SWL vs URS and retrograde vs. antegrade caliceal diverticular stone treatments.
Learning Objectives Upon completion of this activity, participants will be able to: 1. Apply standard therapy to complex problems. 2. Counsel patients and colleagues regarding controversial topics in stone management. 3. Manage all aspects of a complex surgical stone case.
This course will assist Urologists and Allied staff in understanding the evidence-base and the clinical role of the newly-introduced techniques for treating BPH and LUTs. The technology behind each will be reviewed and the quality of the data supporting each will be examined with emphasis placed on the Pivotal trials and their methodology. The current Guidelines will be reviewed and a practical discussion of the peri-operative considerations and tips and tricks for the use of each will be covered.
Upon completion of this activity, participants will be able to: 1. Differentiate between each of the new technologies for treating BPH/LUTS both based on mode-of-action and the quality of supporting evidence. 2. Describe the features expected of a Pivotal Trial for BPH Medical Devices and be able to compare and contrast the findings of these trials for each of the current devices. 3. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each. 4. Upon completion, participants will be able to interpret the current clinical results and the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics. 5. Upon completion, participants will also be able to cite and describe treatments undergoing development for BPH/LUTS.
This course will review the new AUA guidelines on premature ejaculation and delayed ejaculation. The course will provide a clinical framework for the diagnosis, evaluation, treatment and follow-up of patients with ejaculation disorders based on the best available published literature. The course will review correct application of the new AUA guidelines in clinical practice. This course will be a benefit to practicing urologists, primary care providers, other non-physician providers, residents preparing for their certification exam and physicians preparing for their re-certification exam.
Upon completion of this activity, participants will be able to: 1. Analyze the latest evidence on the management of disorders of ejaculation as outlined in the AUA guidelines. 2. Recognize the role of mental health professionals in managing disorders of ejaculation. 3. Improve the diagnostic and therapeutic decision making processes by understanding the evidence basis of these guidelines in urological practice. 4. Acquire in-depth knowledge on the process by which evidence is used to develop scientifically rigorous, yet actionable, guidelines.
This course will address the timely and accurate diagnosis of testicular cancer and emphasize the appropriate integration of pathologic, radiographic and serologic variables in assessing individual patient's risk in both low and high-stage germ cell tumors (GCT). Important features regarding the natural history of GCTs will also be emphasized. Patient selection and treatment options for patients with clinical stage I non-seminomatous germ cell tumors (NSGCT) such as surveillance, 1° retroperitoneal lymph node dissection (RPLND) and chemotherapy will be discussed.
Upon completion of this activity, course participants will be able to: 1. Cite current concepts and controversies in the management of low-stage and high-stage nonseminomatous germ cell tumors (NSGCTs). 2. Discuss current concepts and controversies in the management of low-stage and high-stage seminoma. 3. Describe the biology and clinical implications of teratoma. 4. Illustrate importance of tumor markers and their role in diagnosis, follow up and clinical decision making in testicular cancer.
This interactive webinar will answer questions medical students have regarding facilitation of remote exposure to urology training programs, and the resources available to support urologic education for medical students. Our panel consists of members of the Society of Academic Urologists who will share their insights to help you navigate remote urologic training
This course will focus on what general urologists who have not had fellowship or specialty training in male infertility can do to evaluate and treat male reproductive disorders. Basic science presented will be limited to that which is absolutely essential to understand the basic evaluation and treatment. In 90% of male infertility cases, a good history and careful physical examination, along with a basic semen analysis, which can often be performed by the doctor himself, will allow the general urologist to come up with a tentative diagnosis and treatment plan. More advanced testing is primarily designed to confirm the diagnosis. Key points of history, including inheritance issues, will be discussed. The finer points of physical examination, which in male infertility, due to the ready accessibility of the male reproductive organs to physical examination of a relaxed scrotum, allows the diagnosis to be made without the necessity for imaging studies in the majority of men. Interpretation of semen analysis will be discussed. When and what endocrine evaluations should be performed, including indications for genetic testing such as microY deletion assays and karyotype. When more advanced sperm testing, such as DNA fragmentation and anti-sperm antibody assays, are indicated as well as indications for imaging such a scrotal ultrasound, transrectal ultrasound and testis biopsy. The performance of basic office ultrasound, done by the general urologist, will be explained and the images obtained will be interpreted. The most likely diagnoses resulting from this evaluation will be discussed and treatments that can be employed by general urologists without fellowship training will be gone over in great detail. This will include medical treatments, basic surgical treatments that can be performed by general urologists with minimal microsurgical training and lifestyle recommendations, including supplements that may be of value. A limited presentation of advanced evaluation and treatment methods employed by fellowship trained specialists will be described and the indications for referral to such specialists presented.
Upon completion of the course, participant will be able to: 1. Perform a practical, cost-effective office and laboratory evaluation of the infertile male. 2. Select which medical and surgical treatments are effective and can be employed by general urologists without specialty training. 3. Know when to refer to fellowship- trained specialists, and when to collaborate with IVF doctors. 4. Identify the risk factors for both future infertility and androgen deficiency and how to treat them. 5. Select appropriate diagnostic treatment codes to get the best reimbursements.
This course will teach the urologist and advanced practice provider the skills needed to better communicate with the female patient about her sexual health needs and better manage her sexual dysfunctions. The course will start with normal physiology and pathophysiology of the genitals including how to examine them under magnification in order to better understand sexual dysfunctions in women. Diagnostic tools and treatment strategies for the management of desire, arousal, orgasm and pain disorders including unusual arousal/orgasm issues such as persistent genital arousal disorder will be discussed. Included in this course is an overview of to use the latest FDA approved drugs, off label options, devices such as CO2 fractional laser and surgical therapies. Women with distressing sexual health concerns should undergo biopsychosocial diagnostic evaluations to assess pathophysiology, starting with a history and physical with vulvoscopy. Risks and benefits of hormone therapy for pre- and post-menopausal women will be included, as well as information about neurologic issues affecting sexual function. Also discussed are risk factors for female sexual dysfunction and co-morbid conditions such as genitourinary syndrome of menopause, interstitial cystitis and sexual dysfunction, clitoral phimosis and previous genital surgeries including mid-urethral surgical slings. Women presenting with urologic concerns may, in fact, have sexual dysfunction as the primary issue.
Upon completion of this activity, participants will be able to: 1. Associate basic science principles with physiology and pathophysiology of female sexual function and dysfunction. 2. Apply principles of history and physical examination to the woman with sexual dysfunction. 3. Characterize the consensus paradigms for identification of sexual problems in women, hypoactive sexual desire disorder, and persistent genital arousal disorder developed by the International Society for the Study of Women’s Sexual Health. 4. Diagnose and treat woman with sexual dysfunction presenting in a community setting with FDA-approved and off label medical therapies including estrogen (and progesterone) and androgen therapies as well as centrally-acting drugs. 5. Identify when sexual pain should be treated surgically.
Our ability to diagnose, treat, and manage rUTI has evolved due to additional insights into the pathophysiology of rUTI, a new appreciation for the adverse effects of antimicrobial therapy, rising rates of bacterial antimicrobial resistance, and improved reporting of the natural history and clinical outcomes of acute cystitis and rUTI. This course will review the new AUA guideline on recurrent UTIs in the index female patient. The guidelines encompass rUTI diagnosis, treatment, antibiotic and other methods of prophylaxis. The evidence supporting the guidelines will be presented in a case-based fashion. A treatment algorithm which includes the most current and safe antibiotic regimens will be provided. Faculty are all members of the AUA 2019 guideline panel and include urologists and an internist with expertise in Infectious Diseases.
Upon completion of this activity, participants will be able to: 1. Demonstrate knowledge of the evidence and rationale behind the 2019 recurrent UTI guidelines. 2. Formulate a treatment algorithm for recurrent UTIs in women. 3. Define the concept of antibiotic stewardship, treating patients with the safest methods possible, thereby avoiding collateral damage. 4. Recognize the importance of shared decision making in recurrent UTI management.
Join Drs. Kevin McVary and Charles Welliver with host Dr. Brian Matlaga as they present BPH findings from the Urologic Diseases in America Report.
Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guests: Kevin McVary, MD, Loyola University Medical Center and Charles Welliver, MD, Albany Medical College
This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.
This course on IC/BPS is designed for the urologist, gynecologist, and advanced practice providers who see these patients and are responsible for their medical care. It is designed to focus on what we know, what we have learned from recent research efforts, how we can best use our knowledge in the care of these patients, and what may be coming in the future. We will discuss definition, nomenclature, epidemiology, possible etiology, and review the latest American Urological Association guideline which provides a working framework from which to practice. The issue of phenotyping, an important new focus on clinical trials, will be highlighted. We will review the major findings of the NIDDK Multidisciplinary Approach to the study of Pelvic Pain (MAPP) which is completing a decade of intensive research on this syndrome. How might this research inform and translate into the clinical arena and help our patients.
Upon completion of the activity, participants will be able to: 1. Recall the AUA guidelines and describe how to apply them to care of their patients. 2. Describe the major findings for the 10-year NIDDK MAPP research effort and its current and potential future impact on patient care. 3. Determine how the syndrome is viewed in Europe and identify new treatments and innovations that may impact care. 4. Define the importance of phenotyping patients to improve outcomes. 5. Recognize the controversy regarding whether Hunner lesions comprise a distinct disease.
To utilize a case-based and interactive approach to highlight key components of the current AUA Guidelines for the Medical and Surgical Management of Kidney Stones. The course will additionally provide updated literature and topics in the management of stone disease which may impact future Guideline statements. During this course, representative basic and complex clinical cases/vignettes will be discussed with the use of data from the comprehensive guidelines to demonstrate critical points. Use of the audience response system and Q/A between cases amongst the faculty and audience members will be critical to the success of the course. Important aspects regarding metabolic evaluation, medical management, preoperative evaluation, imaging techniques, and surgical treatment recommendations (as well as surgical approaches and complications) in adult, pediatric, pregnant, and complex patients will be illustrated. The faculty will also reference the Guideline Statements that provide the framework for their decision-making process.
Upon completion of this activity, participants will be able to: 1. Interpret metabolic evaluations for patients with kidney stones, based on an understanding of the published guidelines, and provide appropriate therapy. 2. Demonstrate how to increase the use of medications in the prevention of kidney stones, including understanding potential side effects. 3. Apply dietary recommendations for the prevention of stones. 4. Demonstrate the recommended preoperative evaluation for patients considering kidney stone surgery (including laboratory studies and imaging). 5. Formulate a surgical treatment plan for patients with kidney and/or ureteral stones in adult, pediatric, and pregnant patients, including surgical approach and discussion of complications.
Hav0cEVY5BzlqG7EvgUE
Host: Victor Nitti, MD Guest: David Shin, MD
Chronic orchialgia or testicular pain is a challenging disease to treat for both the patient and urologist because the perception and resolution of pain is often subjective in nature. With a national trend towards treatment away from opioid use, it is important that clinicians utilize an algorithm focusing on non-narcotic use for medication treatment as well as be able to offer office-based or surgical therapies when medical therapy fails. After today’s podcast, learners will be able to: 1. Compare and contrast pathological and non-pathological etiologies of scrotal pain 2. Summarize the rationale for different medication therapies and incorporate an algorithm for treatment 3. Distinguish various surgical treatment options depending upon etiology
Co-Host: Dr. Rena Malik, Assistant Professor of Surgery, Division of Urology and Director of Female Pelvic Medicine & Reconstructive Surgery at University of Maryland School of Medicine
Co-Host: Amy E. Krambeck, MD Michael O. Koch Professor of Urology, Indiana University and IU Health
At the conclusion of this activity, participants will be able to: 1. Interpret metabolic evaluations for patients with stones 2. Determine when to genetically test patients with stones 3. Analyze current gene panels available and options for patients
This podcast was funded by and developed in collaboration with Alnylam Pharmaceuticals, Inc
Join Drs. Brian Matlaga, Kathleen Kobashi, and Una Lee as they discuss urinary incontinence findings from the Urologic Diseases in America Report.
Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guests: Kathleen Kobashi, MD and Una Lee, MD, Virginia Mason Medical Center
This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.
Patrick Hamilton of CMS explains changes to the 2020 Merit-based Incentive Payment System (MIPS) and how this impacts reporting. Additionally, he answers questions from the audience highlighting issues important to urologic practices.
Dr. Eugene Rhee discusses getting your practice up and running with telemedicine on today's podcast. Dr. Rhee's comments include special considerations given the coronavirsus (COVID-19) pandemic's impact on healthcare delivery in the United States.
Dr. Chris Gonzalez discusses considerations for elective urologic surgery given the coronavirsus (COVID-19) pandemic's impact on healthcare delivery in the United States. Dr. Gonzalez is chair of the AUA Public Policy Council.
For more information, please visit the AUA's COVID-19 Information Center. https://www.auanet.org/covid-19-info-center
E.R. Mueller, MD, MSME - Loyola University Chicago Joseph C. Liao, MD - Stanford University J. Curtis Nickel, MD, FRCSC - Queen's University Daniel Shoskes, MD, FRCSC - Cleveland Clinic
This episode provides an introduction to the Urologic Diseases in America (UDA) Report and features perspectives from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guest: Kevin Abbott, MD, MPH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health
This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.
Michel Pontari, MD Lewis Katz school of Medicine at Temple University
AUA2019 Virtual Meeting available now: https://auau.auanet.org/content/aua2019-chicago-virtual-meeting-2019
CME Available: https://auau.auanet.org/node/27477
Course Director: Eric Rovner, MD
Faculty: Kathleen Kobashi, MD Sandip Vasavada, MD
At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various pharmacotherapies for OAB. 2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy. 3. Realize the importance of setting proper patient expectations regarding treatment of OAB and potential need for sequential and even additive therapies. 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents. 5. Discuss potential future pharmacological pathways and therapies for OAB.
This educational series is supported by an independent educational grant from: Astellas
Moderator John Brock, III, MD Professor and Director, Division of Pediatric Urology
Debater - Pro(s) Richard Yu, MD,PHD Harvard Medical School
Mohan Gundeti, MD The University of Chicago
Debater - Con(s) Linda Baker, MD Professor of Urology The University of Texas Southwestern
H. Rushton, Jr., MD Children's National Medical Center-The George Washington University Medical Center
Moderator(s) Jeremy Myers, MD University of Utah
Debater - Pro(s) Hunter Wessells, MD, FACS Professor and Chair University of Washington School of Medicine
Reynaldo Gomez, MD Hospital del Trabajador
Debater - Con(s) Steven Brandes, MD Columbia University Medical Center
Jill Buckley, MD, FACS University of California, San Diego
Moderator: Seth Cohen, MD
Panelists: Gina Badalato, MD Kathleen Kieran, MD Kyle Zuniga (MS4) Vincent D'Andrea (MS4)
2019 AUA Annual Meeting Presidential Address Robert Flanigan, MD, FACS Loyola University Chicago Stritch School of Medicine
2018 AUA Annual Meeting Presidential Address J. Brantley Thrasher, MD, FACS Department of Urology, University of Kansas Health System
2017 AUA Annual Meeting Presidential Address Urology: A Personal Perspective Richard K. Babayan, MD, FACS
Co-Host: Jay Raman, MD, FACS
At the conclusion of these activities, participants will be able to: 1. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC. 2. Facilitate discussions with patients and caregivers regarding RCC treatment options.
CME Available: auau.auanet.org/node/26091
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Yair Lotan, MD
At the conclusion of these activities, participants will be able to: 1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients. 2. Facilitate discussions with patients and caregivers regarding of bladder cancer treatment options.
CME Available: auau.auanet.org/node/26075
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Brian M. Shuch, MD
At the conclusion of these activities, participants will be able to: 1. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer. 2. Explain best practices in RCC patient selection for various treatment options
CME Available: https://auau.auanet.org/node/26099
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Alexander Kutikov, MD, FACS
At the conclusion of these activities, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC. 2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy. 3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC.
CME Available: auau.auanet.org/node/26087
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Alicia K. Morgans, MD, MPH
At the conclusion of these activities, participants will be able to: 1. Recognize cardiovascular comorbidities and describe their management in the context of prostate cancer treatment. 2. Differentiate the roles of the urologist, other specialists and primary care providers in the care of patients with prostate cancer.
CME Available: https://auau.auanet.org/node/26059
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Brian Shuch, MD
At the conclusion of these activities, participants will be able to: 1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 2. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results. 3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.
CME Available: https://auau.auanet.org/node/26054
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Vitaly Margulis, MD
At the conclusion of these activities, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options.
CME Available: https://auau.auanet.org/node/26079
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
The American Urological Association (AUA) and Società Italiana di Urologia (SIU) have collaborated to develop an independent educational activity to review the latest updates in immuno-oncology. This one hour course is designed to improve clinicians’ understanding of current immunotherapeutic agents for the treatment of GU cancers, improve patient outcomes, and the management of adverse events. The course covers the following topics:
Immuno-Oncology: A Focus on Kidney Cancer Immuno-Oncology: A Focus on Bladder Cancer Immuno-Oncology: A Focus on Prostate Cancer Managing Immune-Related Adverse Events
ACKNOWLEDGEMENTS
Independent educational grant support for the webcast and podcast provided by Merck & Co., Inc., Kenilworth, NJ, US
CME Available: https://auau.auanet.org/content/therapeutic-advances-immuno-oncology-2019
Co-Host: William Huang, MD
At the conclusion of these activities, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage the adverse events related to these agents.
CME Available: auau.auanet.org/node/26095
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Take Home Messages: Female Urology/Incontinence Ariana Smith, MD University of Pennsylvania
Take Home Messages: Reconstruction Giulia Lane, MD Urology Fellow, FPMRS University of Michigan
Co-Host: Maxwell Meng, MD
At the conclusion of these activities, participants will be able to: 1. Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their administration. 2. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy. 3. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.
CME Available: auau.auanet.org/node/26067
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Robert Svatek, MD
At the conclusion of these activities, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents.
CME Available: auau.auanet.org/node/26071
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Co-Host: Kelvin Moses, MD
At the conclusion of these activities, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of metastatic HSPC. 2. Describe the risks and benefits of treatment for metastatic HSPC.
CME Available: auau.auanet.org/node/26063
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Please enjoy this free lesson of the AUA Update Series Volume 38 Lesson 1: Diagnosis and Management of Pheochromocytoma
Please send any comments to education@auanet.org
Co-Host: Yair Lotan, MD
At the conclusion of these activities, participants will be able to: 1. Explain the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and describe current clinical trial designs. 2. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.
CME Available: auau.auanet.org/node/26083
This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
Take Home Messages: Infertility/Andrology Sarah Vij, MD Cleveland Clinic Foundation
Take Home Messages: Sexual Dysfunction Faysal Yafi, MD University of California Irvine
Take Home Messages in Endourology/Stones and Transplantation
Endourology/Stones: Nishant Patel, MD UCLA Health System
Transplantation: Nicholas Cowan, MD Urologist, Transplant surgeon Virginia Mason Medical Center
Take Home Messages: Basic Science (Benign) Travis Jerde, PHD Associate Professor of Pharmacology and Toxicology Indiana University School of Medicine
Take Home Messages: Basic Science (Malignant) Donald Vander Griend, PhD Associate Professor The University of Illinois at Chicago
Moderator(s) A. Lenore Ackerman, MD Cedars-Sinai Medical Center
Panelist(s) Toby Chai, MD Professor Yale University School of Medicine
Duane Hickling, MD The Ottawa Hospital, The Ottawa Research Institute
Kimberly Kenton, MD MD, MS Northwestern
Ann Stapleton, MD Professor of Medicine University of Washington
Jennifer Anger, MD, MPH Cedars-Sinai Medical Center
Support provided by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech and Merck
CME Available: https://auau.auanet.org/node/25249
This course will review the most recent AUA practice guidelines for non-muscle-invasive bladder cancer and detail strategies to manage common clinical predicaments involved in the management of these tumors. Specifically we will review: the AUA guidelines; risk stratification and use of cystectomy; selection of the optimal intravesical agent at the right schedule; and treatment of toxicity from intravesical therapy. Practical solutions will be presented that can be readily integrated into the office setting. Emphasis is placed on the evaluation of real clinical cases with open audience participation.
This educational series is supported by independent educational grants from:
AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme
Episode 3: Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents and Radionuclide Therapy and Bone Health
Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents David F. Jarrard, MD
Radionuclide Therapy and Bone Health Steve Boorjian, MD
CME Available: auau.auanet.org/node/25405
The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.
Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme
CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast-0
This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.
Learning Objectives: Diagnose both non-metastatic and metastatic castrate resistant prostate cancer (nmCRPC, mCRPC) and have a working knowledge of treatments and the proper order for administration. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy. Analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of nm/mCRPC. Describe the bone-targeted, radiopharmaceutical agent and its sequencing. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.
This educational series is supported by independent educational grants from:
AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme
Episode 2: Setting Up and Managing Advanced Prostate Cancer in the Community Setting: Unique Challenges and the Role of Chemotherapy, Treatment Sequencing and Future Approaches
CME Available: https://auau.auanet.org/node/25404
The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.
Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme
CME Available: https://auau.auanet.org/node/24579
Instructional Course Director(s) Danil Makarov, MD photo Danil Makarov, MD
New York University School of Medicine
Instructional Course Faculty(s) Michael Barry, MD
Harvard Medical School Angela Fagerlin, MD Chair, Department of Population Health Sciences
Shared Decision Making was recently accepted as the standard of care when counseling patients considering PSA screening by the US Preventative Services Taskforce. Shared Decision Making is also embedded into numerous recently published AUA guidelines (including the localized prostate cancer guideline). In spite of these clear recommendations, Shared Decision Making is not frequently used in clinical practice.
We propose a course that would teach the essentials of Shared Decision Making (SDM) to practicing urologists who help patients decide about prostate cancer screening and treatment. The course will go over the latest research documenting the benefits and drawbacks of Shared Decision Making when counseling patients considering PSA screening as well as treatment approaches for incident localized prostate cancer. It will also teach the participants how to practice SDM with their patients and will engage them in group-based role play. At the end of the session, participants will understand how to apply SDM in their practice.
Learning Objectives: Explain Shared Decision Making. Discuss the impact of shared decision making on patients and on patient-clinician communication. Describe at least one implementation strategy for using shared decision making in clinical practice. Explain Shared Decision Making techniques in a role playing exercise with other attendees. Apply the knowledge they have gained through role play into their routine practice counseling patients.
This educational series is supported by independent educational grants from:
AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme
Episode 1: Genetic Testing in Advanced Prostate Cancer and the Identification of High Risk Disease and Initial Management of Biochemical Recurrence
CME Available: https://auau.auanet.org/node/25403
The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.
Support provided by an independent educational grant from Allergan, Astellas and Medtronic
CME Available: https://auau.auanet.org/node/24584
Instructional Course Director(s) Eric Rovner, MD Medical University of South Carolina
Instructional Course Faculty(s) Alan Wein, MD,PHD Founders Professor and Emeritus Chief of Urology and Director, Residency Program University of Pennsylvania
Christopher Chapple, MD Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield Hallam University
Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 5th International Consultation on Incontinence," as well as European Association of Urology (EAU) Guidelines, has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy. Currently available agents as well as drugs in development will be discussed.
Learning Objectives: Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB) Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy. Realize the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies Analyze the clinical (and theoretical) advantages and limitations of currently available agents Review potential future pharmacological pathways and therapies for OAB
Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme
CME Available: https://auau.auanet.org/content/integrating-care-oncology-patients-establishing-multidisciplinary-oncology-clinic-advanced
This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting. Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression.
Learning Objectives: Describe the components of a multidisciplinary urologic cancer cancer and identify the best structure for the practice. Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer. Demonstrate an understanding of advances in genomic testing and personalized medicine for urologic cancers. Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.
Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme
CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-and-therapeutic-advances-metastatic
Instructional Course Director(s) Michael Cookson, MD, MMHC Professor and Chair University of Oklahoma
Instructional Course Faculty(s) David Jarrard, MD University of Wisconsin
Adam Kibel, MD Brigham Health, Harvard University
William Lowrance, MD University of Utah, Huntsman Cancer Institute
This course will review the important and newly updated 2018 AUA Guidelines on Castration-Resistant Prostate Cancer. This includes a thorough discussion of new trials and approval of agents for MO non-metastatic nmCRPC. In addition, we will review therapeutic breakthroughs in the management of advanced and metastatic hormone naïve prostate cancer (mHSPPC). Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines. Also, the role of genomic classifiers and genetic testing in the evaluation of CRPC, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA CRPC guidelines in those instances. This course will be a benefit to practicing urologists, oncologists, advanced practice providers, and residents/fellows preparing for their certification exam and physicians preparing for their re-certification exam.
Learning Objectives: Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC Understand the sequencing and indications for active treatment with approved agents in the management of nmCRPC Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice Understand and analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer
Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme
CME Available: https://auau.auanet.org/content/chemo...
Instructional Course Director(s) Costas Lallas, MD Thomas Jefferson University Hospital
Instructional Course Faculty(s) Anne Calvaresi, DNP, CRNP Thomas Jefferson University
Edouard Trabulsi, MD, FACS Sidney Kimmel Medical College at Thomas Jefferson University
Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects.
Learning Objectives: Describe the standard of care chemotherapy regimens for genitourinary malignancies Recall both historic and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates. Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies. Recognize and manage the adverse events related to these agents. Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.
Support provided by an independent educational grant from Allergan, Astellas and Medtronic
CME Available: https://auau.auanet.org/node/24581
Instructional Course Director(s) Kathleen Kobashi, MD, FACS, FPMRS Virginia Mason Medical Center
Instructional Course Faculty(s) Sandip Vasavada, MD Professor of Surgery/Urology Cleveland Clinic Glickman Urological Institute and Lerner College of Medicine
David Ginsberg, MD USC Institute of Urology
This course would aim to discuss all guidelines-approved 3rd line therapies for the treatment of overactive bladder (OAB). Case–based discussion will be used adjunctively to illustrate how best to select patients in varying clinical scenarios and how to optimally counsel a patient on each of the available modalities, including onabotulinumtoxinA injection of the bladder, tibial nerve stimulation, and sacral nerve stimulation (SNS). Emerging therapies in neuromodulation will also be introduced.
Optimal patient selection and integration of these therapies into the urology practice will be discussed in detail. Importantly, the technique of onabotulinumtoxinA injection, ideal tibial nerve stimulation, optimal SNS lead placement, and troubleshooting of the failed implant will be highlighted.
Learning Objectives: Name the available 3rd line therapies for treatment of refractory OAB Practice the the injection technique for onabotulinumtoxinA for OAB Employ the technique of tibial nerve stimulation for OAB Indicate the optimal lead placement for sacroneuromodulation and troubleshooting the failed implant Identify the upcoming 3rd line therapies for OAB
Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme
CME Available: https://auau.auanet.org/node/24582
Instructional Course Director(s) Todd Morgan, MD University of Michigan
Instructional Course Faculty(s) Leonard Gomella, MD,FACS Professor And Chair Thomas Jefferson University
Heather Cheng, MD, PhD University of Washington
There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g. PARP inhibition), Urologists are suddenly being confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations (present in greater than 10% of men with metastatic disease). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer.
Learning Objectives: Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.
This educational activity is supported by independent educational grants from: Astellas, Merck and Seattle Genetics
CME Available: https://auau.auanet.org/node/24777
In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of advanced and metastatic urothelial carcinoma while discussing key take-home messages from AUA2019 sessions.
Moderator: Kristen R. Scarpato, MD, MPH, Vanderbilt University Medical Center
Faculty: Anne E. Calvaresi, DNP, CRNP, RNFA, Thomas Jefferson University Siamak Daneshmand, MD, University of Southern California/Norris Comprehensive Cancer Center Anthony C. Wong, MD, PhD, University of California, San Francisco
This educational activity is supported by independent educational grants from: Astellas, Merck and Seattle Genetics
CME Available: https://auau.auanet.org/node/24288
In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of non-muscle invasive urothelial carcinoma while discussing key take-home messages from AUA2019 sessions.
Moderator: Kristen R. Scarpato, MD, MPH, Vanderbilt University Medical Center
Faculty: John L. Gore, MD, MS, FACS, University of Washington Sima P. Porten, MD, MPH, FACS, University of California, San Francisco Chad R. Ritch, MD, MBA, University of Miami
The American Urological Association in conjunction with the National Medical Student Education Curriculum Committee is proud to sponsor a free podcast that will provide exposure to the core concepts and terminology underlying the care urologists provide within Transgender Medicine. This webinar will provide an overview of this complex discipline, and is designed to give medical students the ability to engage in thoughtful discourse with colleagues when caring for this patient population. It will also provide specific insight into the ways Urology is emerging as a leading specialty in this discipline, paving the way for optimization of lifelong care, including before and after surgical reconstruction.
Successful Utilization of Advanced Practice Providers in Urology Practice by AUAUniversity
Defendant(s) Arthur Smith, MD Hofstra University
Moderator(s) Deborah Lightner, MD Mayo Clinic
Expert Witness (Defense)(s) Glenn Preminger, MD Professor and Chief Duke University Medical Center
Expert Witness (Plaintiff)(s) Gregory Auffenberg, MD, MS Memorial Sloan Kettering Cancer Center
Moderator(s) Kevin McVary, MD Southern Illinois University School of Medicine
Panelist(s) Harris Foster, Jr., MD Yale University School of Medicine
Charles Welliver, MD Albany Medical College
Steven Kaplan, MD Icahn School of Medicine at Mount Sinai
Second Opinion Cases (Ask the Guidelines!): Testosterone Deficiency
Moderator(s) John Mulhall, MD Memorial Sloan Kettering Cancer Center
Panelist(s) Robert Brannigan, MD Northwestern University, Feinberg School of Medicine
Landon Trost, MD Mayo Clinic
Emily Kurtz, MD Vanderbilt University Medical Center
AUA2018 Second Opinion Cases in Erectile Dysfunction Moderator(s) Lawrence Hakim, MD, FACS
Panelist(s) Arthur Burnett, MD, MBA, FACS Christian Nelson, PhD Alan Shindel, MD, MAS
AUA2018 Take Home Messages
Minimally Invasive Surgery Presented by: Jean Joseph, MD University of Rochester Medical Center
Imaging Presented by: Simpa Salami, MD, MPH University of Michigan
Take Home Messages from AUA2018 in Pediatrics presented by Emilie Johnson, MD, MPH.
In addition Plenary Next Frontier presentations in the area of pediatric urology
Highlights: Society for Pediatric Urology presented by Caleb Nelson, MD, MPH Journal of Urology Highlights: Pediatrics presented by Julian Wan, MD
This podcast was developed from content delivered during the Use of Novel Hormonal Agents and Systemic Therapy in Advanced Prostate Cancer live course. Topics covered include:
Practical Guide to an Advanced Prostate Cancer Clinic, Presented by Lawrence I. Karsh, MD, FACS Biomarkers for Advanced Prostae Cancer: Ready for Prime Time?, Presented by Daniel W. Lin, MD Acute and Chronic Pain Management in CRPC, Presented by Russell Z. Szmulewitz, MD End-of-Life Issues in CRPC Patients and their Families, Presented by Russell Z. Smulewitz, MD
CME Available: https://auau.auanet.org/node/21876
Immuno-Oncology: A Focus on Prostate Cancer is the fourth webcast in the 4-part series. Topics will include "review of treatment options for advanced disease", "evolution of AR-directed treatment and chemotherapy" as well as "impact of immunotherapy on treatment of advanced disease".
CME Available: https://auau.auanet.org/node/21419
Immuno-Oncology: A Focus on Kidney Cancer is the third in the 4-part series. Topics will include "Review of Treatment Options for Systemic Disease", "Cytoeduction Debate" and "Impact of Immunotherapy on Treatment".
CME Available: https://auau.auanet.org/node/21355
Sequencing of Chemotherapy and Immunotherapy in Advanced Prostate Cancer: Present and Future is the fourth and final in a 4-part series. Topics will include "Role of Chemotherapy and Performance Status and Pain Management" and "Treatment Sequencing, Immunotherapy and Future Approaches".
CME Available: https://auau.auanet.org/node/19911
To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.
The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - How to Properly Administer IO Therapies in an Infustion Suite is the third podcast in a 3-part series.
CME Available: https://auau.auanet.org/node/20964
Immuno-Oncology: A Focus on Bladder Cancer is the second in the 4-part series. Topics will include "non muscle invasive disease" and "muscle invasive disease" as well as "clinical trial evidence" and "future directions and biomarkers" of both.
CME Available: https://auau.auanet.org/node/21348
To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.
The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Managing Patient Side Effects is the second podcast in a 3-part series.
CME Available: https://auau.auanet.org/node/20963
Immuno-Oncology: A New Class of Drugs is the first in the 4-part series. Topics will include "Tumor Immunotherapy", "Immunotherapy Drug Availability and Mechanisms of Action", "Vaccines", "Monoclonal Antibodies" and "Checkpoint Inhibitors".
CME Available: https://auau.auanet.org/node/21336
Androgen Axis Agents and Bone Target Therapies in Advanced Prostate Cancer: What's New is the third podcast in a 4-part series. Topics will include "Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents" and "Radionuclide Therapy and Bone Health".
CME Available: auau.auanet.org/node/19909
Release date:
To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.
The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Biomarkers is the first podcast in a 3-part series.
CME Available: https://auau.auanet.org/node/20962
To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation are producing a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary AUA Castration-Resistant Prostate Cancer Guideline Amendment webinar.
This 60-minute, knowledge-based, live webinar is offered at two different dates and times for the learner's convenience.. The goal of this complimentary webinar is to improve clinicians’ understanding of the 2018 update to the 2013 AUA Guidelines on CRPC. During this webinar, expert Faculty will:
Explore the rigorous process used in the development of these evidence-based guidelines. Discuss new developments and future research needs for this topic. Showcase clinical scenarios in urological practice and the correct application of the new AUA guidelines in those instances.
CME Available: https://auau.auanet.org/node/19903
Take Home Messages from AUA2018
Infertility / Andrology Lawrence Jenkins, MD, MBA The Ohio State University
Sexual Dysfunction Nelson Bennett, Jr., MD, FACS Northwestern University Feinberg School of Medicine
Take home messages from AUA2018 Endourology/Stones: Zeph Okeke, MD Infection/Inflammation: O. Lenaine Westney, MD, FPMRS
To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018).
https://auau.auanet.org/node/20087
In a webinar on Feb. 26, moderator Seth Cohen, MD, and panelists Gina Badaloto, MD, Moben Mirza, MD, Jessica Kreshover, MD, and Taylor Kohn (MS4) provide an overview on the application cycle to the Urology Match Program and offer advice for urology candidates seeking to maximize their efforts during this process. They also answer questions about the process for selecting away rotations and offer insight into the various aspects of different training experiences.
Emerging Treatment of M0 CRPC: Update on the AUA/SUO Guidelines is the second podcast in a 4-part series. Topics will include “M0 CRPC: Emerging Treatment Options” and “MDC and Review of CRPC Guidelines”.
CME Available: auau.auanet.org/node/19907
The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know is the first podcast in a 4-part series. Topics will include "Initial Management and Imaging of Advanced Prostate Cancer" and "Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer ".
CME Available: https://auau.auanet.org/node/19906
This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.
CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast
This course will provide a practical, evidence-based approach for the management of everyday problems in the management of prostate cancer, using a case-based approach with examples from real practice. Cases will illustrate contemporary management of early and late stage disease with emphasis on how new molecular diagnostic and prognostic tests (PCA3, MDx Confirm, Mitomics, Prolaris, Oncotype Dx Prostate, Decipher, and others) can be used for improved clinical decision making in screening, decisions on initial biopsy and rebiopsy, choosing and following men for active surveillance, and managing PSA failures. In addition, best practice use of newer agents for management of castrate-resistant disease will be reviewed, including the potential for use of targeted therapies based on genomic analysis of advanced tumors. The course will be of interest to individuals at all levels of clinical experience.
CME Available: https://auau.auanet.org/content/management-prostate-cancer-case-based-approach-emphasis-integrating-new-molecular-7
The goal of the course is to provide both a basic and real-world application of immunotherapy for genitourinary oncology. The course is directed towards the urologist with an interest, but no prior experience delivering immunotherapy agents to patients with bladder and kidney cancer (with possible application to prostate cancer in the future). Starting with innovating breakthroughs, new therapies and their side-effects, the course will also cover common side-effects and biomarkers to risk stratify patients. We will plan to discuss real world-challenges in starting an immunotherapy program, from regulatory requirements to coding and billing for systemic therapies.
CME Available: https://auau.auanet.org/content/immunotherapy-urologist-basic-principles-adverse-effects-drug-delivery-webcast-019ic-2018
This course will offer a review of what faculty believe are the most important articles in the English-speaking literature on prostate cancer from May 2017 to April 2018. Focus will be placed on articles that have relevance to clinical practice, including both research and clinical articles.
CME Available: https://auau.auanet.org/content/prostate-cancer-update-webcast-063ic-2018
Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, and prostate cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a panel discussion with an interactive component. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects.
CME Available: https://auau.auanet.org/content/chemotherapy-immunotherapy-options-genitourinary-malignancies-primer-advanced-practice
We will discuss common PSA dilemmas: 1. Who should be screened? 2. What is the role of MRI in biopsy naive and men with prior negative biopsy? 3. What other markers can be used to determine whether biopsy or rebiopsy is warranted? 4. Whats the optimal biopsy strategy: Transrectal, transperineal, MRI-cognitive, MRI fusion? 5. Discuss Active Surveillance, Rad Px, XRT and focal therapy pros and cons for PSA-detected cancer. 6. What is role of adjuvant v. salvage XRT post-RP? 7. Review new PET scans for biochemically recurrent disease after RP or XRT. 8. Discuss roles of ADT, chemotherapy, and other agents (PARP inhibitors, vaccines, immunooncologic agents) in men with advanced and metastatic disease.
CME Available: https://auau.auanet.org/content/management-common-dilemmas-prostate-cancer-diagnosis-staging-treatment-webcast-058ic-2018
The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area. Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer. Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologist.
CME: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-coordination-care-patients-journey-2018
Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 5th International Consultation on Incontinence," as well as European Association of Urology (EAU) Guidelines, has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy. Currently available agents as well as drugs in development will be discussed.
CME Available: https://auau.auanet.org/content/contemporary-pharmacotherapy-oab-webcast-031ic-2018
Dr. Nitti and Dr. Davis discus the use of focal therapy in the treatment of prostate cancer. @jdhdavis - This file has been updated
The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area. Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer. Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologists.
CME: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-evolving-landscape-adjuvant-therapy-2018
The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area. Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer. Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologist.
CME Available: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-roles-urologist-and-medical-oncologist-2018
This course will review the 2015 update to the 2013 AUA guidelines on castration-resistant prostate cancer. Faculty will explore the rigorous process used in the development of these evidence-based guidelines, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA guidelines in those instances. This course will be a benefit to practicing urologists, non-physician providers, residents preparing for their certification exam and physicians preparing for their re-certification exam.
CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-webcast-074ic-2018
The American Urological Association (AUA) recognizes the critical role of the primary care provider in treating patients with urologic conditions. The AUA is pleased to offer this Podcast on one of the urologic topics most relevant to front-line patient care—Overactive Bladder (OAB). This OAB Podcast, recorded live at the 2018 AUA Annual Meeting, was recorded specifically for primary care providers and explores the following topics: the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy; currently available agents as well as drugs in development; patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms; and more. Get the latest updates on this topic from the experts! You can also earn free CME for this Podcast! You can easily create an AUA account and earn free CME for this Podcast.
Access at https://auau.auanet.org/AUA2018/contemporary-pharmacotherapy-oab-broadcast.
Steven A Kaplan, MD joins Dr. Nitti to discuss Minimally Invasive Treatment Of BPH. Dr. Kaplan is Professor of Urology at the Icahn School of Medicine at Mount Sinai and Director of Benign Urologic Diseases and The Men’s Health Program of the Mount Sinai Health System.
Dr Nitti and Dr. Daneshmand discuss the AUA Update Series Article titled "Update on Medical and Surgical Management of Advanced Testis Cancer"
This episode will describe and explain the current recommendations for imaging; indications for post-chemotherapy retroperitoneal lymph node dissection; the IGCCCG (International Germ Cell Cancer Consensus Group) risk classification; and pros and cons of 3 cycles of cisplatin, etoposide and bleomycin vs 4 cycles of etoposide and cisplatin EP for IGCCCG good risk disease.
Dr. Tanya D. Dorff presentation on Treatment Sequencing and Combinatorial Strategies in CRPC
Acknowledgements The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:
Astellas AbbVie Genomic Health Sanofi Genzyme Tolmar Pharmaceuticals, Inc.
CRPCProstate CancerAUA
Dr. Adam S. Kiebel presents a presentation on the 2017 AUA CRPC Guideline. Dr. Kibel is Chief of Urologic Surgery at both the Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, he is Elliot Carr Cutler Professor of Surgery at Harvard University School of Medicine, Chairman of the Harvard Program in Urology Residency Program (Longwood) and Co-Leader of the Prostate Cancer Program for Dana Farber/Harvard Cancer Center. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland.
Acknowledgements The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:
Astellas AbbVie Genomic Health Sanofi Genzyme Tolmar Pharmaceuticals, Inc.
AUA2017 Court is in Session: Myocardial Infarction on Androgren Replacement Therapy by AUAUniversity
Court is in Session: Colostomy after Robotic Prostatectomy Speaker: Christopher P. Evans, MD
AUA2017 Take Home Messages: BPH/LUTS - Minimally Invasive Surgery - Quality by AUAUniversity
AUA2017 Take Home Messages: Bladder Cancer - Transplantation - Female Urology by AUAUniversity
AUA2017 Take Home Messages: Pediatrics | Penile/Urethral Cancer | Kidney Cancer by AUAUniversity
AUA2017 Take Home Messages: Infertility/Andrology | Outcomes | Sexual Dysfunction by AUAUniversity
AUA2017 Take Home Messages: Prostate Cancer, Basic Sciences, and Trauma/Reconstruction by AUAUniversity
Bladder Cancer Immunotherapy Series: Immunotherapy: From Research to Practice #1 by AUAUniversity
The goal of this knowledge-based activity is to improve clinicians' understanding of current immunotherapeutic agents for the treatment of bladder cancer and to increase their ability to improve patient outcomes and the management of adverse events. Educational grants provided by the following corportations: AstraZeneca, Bristol-Myers Squibb, Genentech, Merck